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ABSTRACT 
Vaccines against the arthropod-borne dengue virus (DENV) are still 
commercially nonexistent. A subunit immunization strategy may be of value, especially 
if a safe viral vector acts as a biologically active adjuvant. The DENV envelope protein 
(E), the main target for neutralizing immune responses, has three conformational 
domains. The immunoglobulin-like and independently folding domain III (DIII) contains 
epitopes that elicit highly specific neutralizing antibodies. The hepatitis B small surface 
antigen (HBsAg, S) was used as a scaffold to display DENV 2 DIII on a virus-like 
particle (VLP). A measles virus (MV) was engineered to vector HBsAg and the hybrid 
glycoprotein DIII-HBsAg in two different loci (DIII-S). Despite the relatively deleterious 
effect on replication caused by the insertion of two transcription cassettes, the 
recombinant virus MVvac2(DIII-S,S)P induced the secretion of DIII-S hybrid VLP with 
a similar sucrose density as HBsAg particles (1.10-1.12g/ml) and peaked at 48 h post-
infection producing 1.3x10
6
 TCID50/ml infectious MV units in vitro. A second 
recombinant virus, MVvac2(DIII-S)N, was engineered to vector only the hybrid DIII-S. 
However, it did not induce the secretion of hybrid HBsAg particles in the supernatant of 
infected cells.  The immunogenicity of the recombinant viruses was tested in a MV-
susceptible small animal model, the experimental group which received two 10
5
 TCID50 
I.P. doses of MVvac2(DIII-S,S)P in a 28 day interval developed a robust immune 
response against MV (1:1280), HBsAg (787 mIU/ml) and DENV2 (Log10 neutralization 
index of 1.2) on average. In summary, it is possible to display DENV E DIII on hybrid 
HBsAg particles vectored by MV that elicit an immune response. This forms the basis for 
a potential vaccine platform against DENV.  
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Chapter 1. Introduction 
1.1 Dengue Epidemiology. Dengue is the most important arthropod borne viral 
disease in the world. It is caused through infection by dengue virus (DENV). In 2013, it 
was estimated that 390 million people has been infected with DENV, causing 96 million 
clinical cases annually (1). Dengue has become endemic in various countries in the 
Americas, the Middle East, Africa, the Western Pacific and Southeast Asia (2). About 
40% of the world’s populations live in locations that are highly at risk for the 
transmission of DENV (Fig. 1). Areas at risk are mainly tropical or sub-tropical bearing 
the optimal breeding ground for the arthropod vectors that transmits DENV, which are 
the mosquitoes: Aedes aegypti and Aedes albopictus (3). 
 
 
 
Figure 1. Diagram Showing a World Map Highlighting Countries where Dengue Virus is 
Prevalent.  Dengue is endemic in over 100 countries. The three different shades of red indicate the 
level of prevalence of the virus in each country. Dengue and dengue hemorrhagic fever are prevalent 
in urban and suburban areas in the Americas, South-East Asia, Eastern Mediterranean, and Western 
Pacific; it is mainly prevalent in rural areas in Africa (3). 
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Modernization and societal changes have aided in the geographic expansion of the 
mosquito vectors. These changes include globalization, increased international travel, as 
well as unplanned urbanization (2). Unplanned urbanization has pushed human dwellings 
to invade the rainfall forest, placing humans in mosquitoes’ home environment, which 
increases exposure rate (4). In addition, inadequate waste and sewer management, along 
with lack of a vector control program that is usually present in unplanned urbanizations 
exacerbate epidemic activity of DENV (2). These types of scenarios can be seen in 
developing countries where DENV infections run rampant, like the Philippines, Thailand, 
and Vietnam, which are the Asian countries that has the highest dengue prevalence (2). In 
these countries, DENV infection is one of the top 10 causes of death in hospitalized 
children (5). In addition to the burden that DENV infection place on the health care 
system of each country, it also imposes a high economic burden on the country’s 
government and on each individual (3). In Southeast Asia, clinical DENV infection cause 
an annual economic burden of ~$950 million. Therefore a reduced transmission of 
DENV would greatly lessen the burden placed on both the healthcare system and the 
economic stability of developing countries where DENV infection is endemic.  
Many other factors have been associated to the 30-fold increases in DENV 
prevalence in the past 50 years. The main factor being the expansion of the habitat for A. 
aegypti and A. albopictus; due to globalization, international travel, climate changes, 
arthropod vector’s adaptation, etc. In the U.S. recent outbreaks have happened in Hawaii 
in 2001, Texas in 2005, and Florida in 2009 to 2011 (6). In 2010, the 1
st
 cases of DENV 
infections due to indigenous transmission in Europe was reported (2). This was 
acknowledged to be caused by A. albopictus whose eggs have adapted to the subfreezing 
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temperature in Europe. All of these factors only magnify the dire need of a viable vaccine 
against DENV as the habitats for the vector transmitting DENV broaden (6). Most severe 
cases of DENV infection reported annually originate from the Asia-Pacific region, the 
Americas, and Africa; where there is a high concentration of all four heterologous 
serotypes circulating (7). In addition, the spread of the different DENV serotypes have 
steadily increased all over the world in recent years (Fig. 2). The increase in international 
travel have aided in the spreading of the mosquito vectors that transmits DENV; this 
includes the movement of the virus in infected individuals who travels internationally as 
well as cases where the mosquito vector’s eggs were unknowingly transported in tires 
Figure 2. Two World Maps Presenting the Increased International Distribution of the Four 
Different Serotypes of DENV, Over 34 Years.  The top world map shows that only one area of the 
world, the Asia-Pacific region, have all four DENV serotypes circulating. 34 years later, the bottom 
world map shows that now the majority of the world harbors all four DENV serotypes (8). 
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being shipped overseas (8). The broadening of the habitat for A. aegypti and A. albopictus 
have also been encouraged by international travel, where they become adapted to their 
new environment. The expansion and development of human housings into the natural 
habitat for these vectors have also increase the rate of exposure between humans and 
mosquitoes (8). Overall, many factors have encouraged the increased distribution of 
DENV, which have promoted more frequent and larger dengue epidemics that are 
associated with more severe symptoms of the illness. 
1.2 Transmission of Dengue Virus.  DENV is an arbovirus, transmitted by the 
bite of female mosquitoes, specifically: A. aegypti and A. albopictus (2). A. aegypti 
originated from Africa and has now spread throughout most of the world, whereas A. 
albopictus originated from Southeast Asia, with a cold-resistant strain in Europe (5). 
Transmission of DENV happens during the feeding activity for these female mosquitoes, 
which peaks in the morning time and late afternoon. The virus is transported from person 
to person while these mosquitoes have their blood meal, at which point the virus is 
subcutaneously injected into the person (2).  The transmission is carried exclusively by 
female mosquitoes due to their dependence on blood for oviposition.  It has been 
demonstrated that there is vertical transmission from infected females to their ova, this is 
the main mechanism that explain the persistence of infected mosquitoes during winter in 
some non-tropical regions. Male mosquitoes feed from fruit. 
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Viremia, the presence of a high titered virus in the bloodstream, can usually be 
observed 24-48 hours before the appearance of clinical symptoms. Viremia may last up to 
10 days in patients infected with DENV (2). If the mosquito feed on an individual with 
viremia, the mosquitoes can become infected by DENV which will target the epithelial 
cells of the mosquito’s mid-gut (2). These mosquitoes will then become infectious, after 
an incubation period of 8-10 days post-feeding. After spreading systemically through the 
haemocele, DENV reaches the salivary glands where it can be easily transmitted to 
humans (2). In summary, the mosquito can transmit DENV by directly changing host 
during a blood meal or after 8-10 days when DENV has multiplied in the salivary glands 
(Fig. 3). The mosquito will then be able to transmit DENV for the rest of its life in 
addition to the possibility of transmitting DENV to its eggs, as mentioned (5). 
 
 
Figure 3. Timeline Representing the Transmission of DENV, Following the Feeding Schedule 
and Life Cycle of the Mosquito Vector. A mosquito may obtain DENV when it feeds from a 
viremic host, who has a high titer of DENV in their bloodstream, enough to be taken up by the 
mosquito. Mosquito may infect a second host if it directly takes another blood meal after it obtained 
DENV. As well as after 8-10 days post-blood meal from a viremic first host, because the DENV 
would have had time to replicate and reach the salivary gland of the mosquito [CDC].  
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Initially in humans, DENV targets macrophages and dendritic cells (DC) because 
they are present in the epidermis and subcutaneous tissue where the virus would be 
injected by the mosquito (2). The infected macrophages and DCs will then migrate to the 
lymph node (LN) where the virus will spread to other macrophages and ultimately 
peripheral monocytes. This will result in the first viremia, as viruses are moved in 
draining and remote LN. The major sites of viral replication for DENV in humans are 
posited to be DCs, macrophages, and monocytes. In addition, DENV may also be found 
in other tissues throughout the body, such as the lungs, the liver, the spleen and the 
kidneys (2). Cells that are infected with DENV usually die through apoptosis or necrosis. 
Necrosis causes the increased production of toxins which in turn will activates the 
fibrinolytic and coagulation systems. Viremia, platelet dysfunction, and severe 
thrombocytopenia, will result in the fragility of the capillaries, presented as bruising, 
petechiae, and gastrointestinal mucosal bleeding; these are the characteristics of DHF (9). 
In addition, increased vascular permeability and coagulopathy is amplified when IgM 
antibodies reacting with the epithelial cells (EC), platelets, and plasmin are produced. 
During secondary infection, enhancement of infection by IgG (discussed below) will 
contribute to the high viral load that will lead to the secondary viremia (9).  
1.3 Dengue Virus Structure and Replication Cycle. DENV is a member of the 
family of Flaviviridae; It is an enveloped virus that has an icosahedral nucleocapsid 
containing ~10.7kb of positive-sense, single-stranded RNA as genome (1). This encodes 
a polyprotein that will be cleaved into seven nonstructural proteins and three structural 
proteins that will be processed co- and post-translation by cellular and viral encoded 
proteases. The three structural proteins are C, pre-M/M, and E proteins. The seven 
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nonstructural proteins are NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5 (2). The 
capsid protein (C protein) serve as RNA chaperone and binds at a high affinity with the 
viral RNA; this protein is confined to the nucleus and nucleoli when independently 
expressed on its own in infected cells. The pre-membrane or membrane protein (pre-M/M 
protein) plays a vital role in viral fusion and entry; it has been shown that mutations in 
the M protein resulted in lower rates of virus assembly and entry (2). The envelope 
protein (E protein) in DENV lies parallel to the surface of the virion. Since it has been 
shown that anti-E antibodies will neutralize viral infectivity through the inhibition of viral 
binding to cells, the E protein has been concluded to play a vital part in virus attachment 
and virus-specific membrane fusion (10). In addition, it has been observed that the E 
protein’s stem region plays a vital role in heterodimerization of pre-M, hence affecting 
membrane binding and virus assembly (2). The non-structural protein 1 (NS1) is 46 kDa, 
it is a glycoprotein that co-localizes with double-stranded RNA (dsRNA) in mammalian 
and insect cells, which makes it vital for viral replication. The non-structural protein 2-A 
(NS2A) is 22 kDa, it is important in the replication of the genome, RNA. The non-
structural protein 2-B (NS2B) is 14 kDa, it is a membrane associated protein that is a 
required cofactor for the NS3 protein, as it recruits NS3 to the endoplasmic reticulum 
(ER) membrane. The non-structural protein 3 (NS3) is 69 kDa, it serves as a 
multifunctional viral protease; it has the protease domain at the N-terminal and a domain 
that includes nucleoside triphosphatase (NTPase), RNA triphosphate (RTPase), and 
helicase activities at the C-terminal. The non-structural protein 4-A (NS4A) is 16 kDa, it 
co-localizes with NS3 and the viral dsRNA in cytoplasmic foci, which contains viral 
replication complexes. Constitutes a cofactor for the viral protease. It may be important 
8 
 
in formation of replication vesicles, making it a viral membrane protein. The non-
structural 4B (NS4B) protein weighs 28 kDa, it also co-localizes with NS3 and the viral 
dsRNA at the site of RNA replication. The non-structural protein 5 (NS5) is the largest 
protein (105 kDa). NS5 is also the most conserved protein because it encodes the RNA-
dependent RNA polymerase (RdRp) on its C-terminal domain, which makes it vital for 
viral RNA synthesis; methyltransferase (MTase) and guanylytransferase (GTPase) are 
also encoded on its N-terminal domain. In addition, this protein is also involved in 
counteracting the interferon (IFN) system of the innate immune response (2, 5, 6).   
During host cell infection, DENV enters the cell via clathrin-dependent receptor-
mediated endocytosis (3). After endocytosis, the environment inside the endosomes 
becomes acidified, which causes a pH-dependent conformational change that rearranges 
the E and M proteins prompting a class II membrane fusion machinery; exposing the 
fusion loop into the endosomal membrane (Fig. 4). This allows the fusion of the viral 
envelope with the endosomal membrane; releasing the viral nucleocapsid into the 
cytoplasm (2). The nucleocapsid will then dissociate in the cytoplasm, releasing the viral 
RNA to be translated by the ribosomes on the rough ER. The polyprotein is then 
translated and co-translationally processed and cleaved by host and viral proteases into 
the respective structural and non-structural viral proteins. The RdRp generates the 
negative complementary strand to the viral genome, which will be used as a template to  
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Figure 4. Diagram Representing the Replication Cycle of DENV in Infected Host Cell. DENV 
binds to the host cell’s surface receptor and enter the cell via receptor-mediated endocytosis. The 
acidification of the internal environment of the endosome allows for the rearrangement of the DENV 
E and M protein, resulting in the fusion of the viral envelope with the endosomal membrane. Hence, 
the viral RNA is released into the cell cytoplasm. The viral genome is then translated creating a 
polyprotein, which is cleaved into the respective 3 structural and 7 non-structural viral proteins. The 
RdRp encoded by NS5 generates the complementary strand to the viral genome for viral replication. 
The viral RNA will then associate with capsid proteins to form the nucleocapsid. The nucleocapsid 
will associate with the E and pre-M rich ER membranes and buds into the ER lumen to create 
immature virion. This will exit the cell via exocytosis through a secretory pathway (2). 
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replicate more copies of the viral RNA. The nucleocapsid is then formed by the 
association of the viral RNA with the capsid protein. The nucleocapsid buds into the 
lumen of the ER and obtain the lipid membrane proteins pre-M/M and E (2, 3). After the 
assembly of the immature virions, it is transported out of the host cell through the 
classical secretory pathway. The viral particles will be contained in a vesicle, transported 
through the Golgi stacks and secreted by exocytosis. During its transport through the 
trans-Golgi network (TGN), the protease furin cleaves the pre-M protein to its mature 
form, M protein that remains on the mature and infectious virion.   
1.4 Manifestation of Symptoms in Dengue Virus Infected Patients. There are 4 
different serotypes of DENV: DENV-1, DENV-2, DENV-3, and DENV-4 (1). The 
presence of multiple serotype represents a challenge in controlling illnesses and 
symptoms in patients infected with DENV as well as in creating a viable commercial 
vaccine with complete protection against DENV. Clinically, DENV infection has been 
divided in two main syndromes: Classic Dengue and severe Dengue infection. The 
patient can evolve clinically from non-significant, dengue fever (DF), to the extremes of 
dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) (4). After infection 
with a mosquito bite, an individual may be asymptomatic, or may develop initially a flu-
like syndrome. In most cases, the infection will be resolved without any complications 
(1). The majority of severe DENV infection cases will result in DF, where the symptoms 
include: sudden onset of fever reaching 102.2ºF, headache, myalgia, macular or 
maculopapular rashes, joint pains, body aches, and retro-orbital pain (5, 6). Usually, this 
acute phase is limited to last only 1 week, followed by recovery. However, 1% to 7% of 
DENV patients may develop DF with hemorrhage, where symptoms include: petechial 
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purpura, ecchymosis, and epistaxis. Furthermore, up to 2% of DENV patients may 
develop the more severe and life-threatening DHF, where complications include: 
increased vascular permeability, liver damage, thrombocytopenia, and hemorrhaging 
from the skin, gum, nose, and gastrointestinal tract. These cases may also worsen and 
progress to DSS, where a redistribution of the effective central vascular volume towards 
the periphery is caused by vasodilatation and diapedesis, resulting in a sudden drop in 
effective perfusion pressure (2). The main problem in DHF or DSS is not blood loss but 
intravascular fluid loss. Therapy at this stage of symptoms is the management of blood 
volume and blood pressure. The current therapy for patients infected with DENV is 
focused on support, mainly with bed rest, fluid intake, and the control of fever or pain 
with antipyretics and analgesics. In mild cases, patients with DENV infection will 
respond in one or two days after plasma expansion with isotonic saline solution (5).   
1.5 Enhancement of Pathogenesis. Pathogenesis in an individual infected with 
DENV may be enhanced due to the existence of the four different serotypes. Two 
different pathways of pathogenesis enhancement non-mutually exclusive have been 
considered: antibody dependent enhancement (ADE) and the original antigenic sin. Upon 
DENV infection, serotype-specific life-long immunity is acquired; however it will only 
confer a transient immunity against another serotype (11). Studies have shown that 
antibodies elicited from a primary infection are a major factor in the rapid development 
of the more severe DHF and DSS after a secondary infection with a heterologous 
serotype (12, 13).  
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The explanation for ADE is that the non-neutralizing, cross-reactive antibodies 
gained from the primary infection will bind to the heterotypic virus (1, 9, 13). The 
antibody-virus complex will increase the uptake of the viral particle by Fc-receptor 
expressing cells such as monocytes, macrophages and DCs (Fig. 5). This will in turn 
increase the viral replication and increase the severity of infection (14). In addition, ADE 
may also occur in situations when there is a low antibody concentration or when there is 
low antibody avidity for the current DENV infecting serotype. Specifically, when the 
amount of antibodies bound the virion is below the amount needed for neutralization, 
which is a minimum of ~30 for each virion (1, 2). The occurrence of ADE has been 
supported through its observation in vitro; where non-neutralizing antibodies that were  
specific to DENV were able to increase viral replication in peripheral blood leukocytes 
(6). In addition, ADE incidences in vivo have also been observed in monkey. Scientists 
observed a higher viral load in monkeys that received a passive transfer of humanized 
anti-DENV monoclonal antibody or human sera that are immune against DENV (6).  
Figure 5. Diagram Representing the Stages Leading to Antibody-dependent Enhancement. 
Cross-reactive heterotypic antibodies from the primary DENV infection bind to the viral particles 
from the current DENV infection. These antibodies are non-neutralizing that creates an Ab-virus 
complex which enhances its uptake by Fc-receptor expressing cells such as monocytes, 
macrophages, and DCs. Resulting in an increased viral load (14). 
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Original antigenic sin occurs when pathogenesis enhancement is mediated by the 
cellular immune response (2). Scientists have found that the memory T cells that are 
specific for DENV serotype responsible of the primary infection may be reactivated due 
to cross-reactive characteristics. These T cells show suboptimal degranulation, but it will 
induce an increased secretion of cytokines, resulting in apoptosis of infected and non-
infected bystander cells (6). This excessive activation of the cellular immune system 
causes a cytokine storm, which increases vascular permeability. This reaction has been 
concluded to be the main reason behind life-threatening DSS cases (1, 2, 6).  
Since all of the DENV vaccines that are most developed target the humoral 
immune system, ADE is the major cause of difficulties in the generation of a vaccine 
against DENV. This created a fear in the production of DENV vaccines because a 
vaccine that could not generate an equilibrated neutralizing immunity against all four 
serotypes could increase the risk of vaccinees developing the more severe and life-
threatening DHF and DSS. Therefore it has been concluded that a tetravalent vaccine is 
mandatory (15). A successful vaccine against DENV must induce a balanced and long-
lasting immunity against all four of the heterologous DENV serotypes. In addition, it 
must target an antigenic epitope on DENV, which is conserved in all four DENV 
serotypes, yet also be highly specific to each serotype to avoid cross-reactivity. This 
challenge in creating a safe vaccine for DENV has resulted in a lack of commercially 
available vaccines against DENV, which has been approved. 
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1.6 Various Approaches to Creating a Vaccine and its Challenges. An ideal 
dengue vaccine must have a couple of vital characteristics. First, it must be a tetravalent 
vaccine formulation and induce a long-lasting balanced immune response to each 
serotype. The vaccine should also be safe in 9-12 months old children, so it can be used 
as a pediatric vaccine, since this is the population most at risk of complicated Dengue 
infections. A vaccine that can be produced at a low cost with high efficiency for the ease 
of scaling up production would also be desirable (10). The main targets that have been 
used in vaccines against DENV infection in humans are the pre-M-E, and NS1 proteins 
(Fig. 6). The pre-M protein creates a heterodimer with the E proteins and is cleaved when 
the virion matured. The M protein is completely inaccessible for antibody binding 
because it is hidden beneath the E protein dimer. However, in some cases where 
incomplete cleavage of pre-M by furin results in partially mature/immature virion, this 
Figure 6. Illustration of the Three Main DENV Proteins Targeted for an Antibody Response 
and the Function of those Specific Antibodies. Antibodies against the envelope protein of the 
mature virion is found to be neutralizing, but may induce antibody-dependent enhancement. 
Antibodies against the pre-M protein on the immature virion are found to be serotype cross-reactive 
and may induce antibody-dependent enhancement. Antibodies against NS1 will cause complement-
dependent lysis of the infected host cell (1).   
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can be recognized by M protein-specific antibodies. Yet, antibodies against the pre-M 
protein are very cross-reactive across the four different serotypes (1). The NS1 protein 
has a multimeric structure and it can be found displayed on the surface of the infected 
host cells or released as a soluble particulates. Although antibodies for NS1 are very 
serotype specific, this glycoprotein is not incorporated into the virion; leading scientists 
to conclude that ADE can be avoided by utilizing NS1 as the target epitope. In addition, 
antibodies against NS1 also cause complement-dependent lysis of the DENV infected 
host cell (1).  The E glycoprotein is the main membrane surface component of DENV. In 
its tightly packed mature form the cross reactivity of the E protein is controlled by the 
dimeric conformation on the virion surface. Each virion is composed of ninety dimers 
tightly packed with an icosahedral symmetry, which limits the accessibility of epitopes to 
bind antibodies. It has been found that antibodies against the E protein after the first 
DENV infection are very serotype cross-reactive. These antibodies are also short-lived, 
since most of them are not represented in the memory immune response that protects the 
individual against the serotype that caused the prime infection. Structurally, it has been 
described three domains in each monomer of E. The fist two domains are not sequential 
and represent antibody epitopes with a high cross-reactive potential. However, domain III 
(DIII) of the E protein has the highest variable in amino acid sequence between the four 
different serotypes. Therefore, it has been observed that antibodies specifically against 
DIII of the E protein are highly serotype-specific. 
 In addition to ADE, there are multiple challenges that are faced in the production 
of a DENV vaccine. The mechanism of protective immune response against DENV is not 
completely understood (16). In addition, vaccine development is further halted due to the 
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lack of animal model for DENV. Normal mice infected with human DENV do not show 
measurable viremia or disease (17, 18). Therefore researchers have to use a mouse 
adapted strain of the virus or infect an immunocompromised mouse model (17). Some 
have argued the relevance of the results from these studies lacking a reliable animal 
model when applied to human infection.   
Despite these challenges, there are multiple DENV vaccine platforms that have 
been pursued and some of which have been approved for clinical testing. These include 
live attenuated virus (LAV), purified inactivated virus (PIV), recombinant subunits, 
virus-like particles (VLPs), and plasmid/viral vectors. LAV vaccines make up the 
majority of vaccine candidates in clinical trials (Table 1). It has been shown to produce a 
large, long-lasting, and broad humoral and cellular immune response. DENV strain for 
LAV were generated by some research groups through serial passaging in tissue culture, 
and these were found to induce T cell and antibody responses that are similar to those 
caused by a natural infection (1). However, it has been difficult for LAV vaccines to 
achieve a balance between an optimal level of attenuation and a low level of 
reactogenicity (16, 17). The top 3 most developed DENV vaccines are the recombinant 
LAV from Sanofi Pasteur, the US National Institute of Health (NIH), and the US Centers 
for Disease Control and Prevention (CDC) – partnered with Inviragen (Fig. 7). The 
vaccine developed by Sanofi Pasteur utilized the attenuated vaccine strain 17D of the 
yellow fever virus (YFV) as the backbone of their recombinant virus. They replace the 
gene encoding pre-M and E proteins with those from each DENV serotypes (1). The 
vaccine developed by the NIH utilizes the attenuated version of DENV-1, 3, and 4 
genome, the attenuating mutation can be found in the 3’ untranslated region (UTR). 
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However, they developed a recombinant LAV against DENV-2, they utilized the genome 
of DENV-4 as the backbone and replaced the pre-M and E gene with those of DENV-2. 
The vaccine developed by CDC-Inviragen utilized the DENV-2 genome as the backbone 
of their recombinant virus; replacing the pre-M and E gene with those of DENV-1, 3, and 
4 (1).  
 
 
 
 
Figure 7. Diagram Representing the Different Approaches that has been done to Create a 
Viable Tetravalent Vaccine against DENV. At the top is the DENV RNA genome. The Sanofi 
Pasteur vaccine used the vaccine strain of yellow fever virus (YFV17D) as the backbone, replacing 
the pre-M and E gene with the respective pre-M and E gene from each DENV serotype. The NIH 
vaccine used attenuated DENV genome, as well as a replacing the pre-M and E gene of the DENV-4 
genome with those of DENV-2. The CDC-Inviragen vaccine used attenuated DENV-2 genome as the 
backbone, replacing the pre-M and E gene with those of DENV-1, DENV-3, and DENV-4. The 
newer approach to creating a DENV vaccine is in using plasmids or viral vectors to only express the 
E and pre-M gene (1). 
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The results from the clinical trial for some of these vaccines found a problem seen 
in tetravalent vaccines, where the simultaneous vaccination with all 4 different serotypes 
caused an inter-serotype interference. The consequence was observed in viremic patients 
caused by one or two dominant serotype with higher viral replication fitness compared to 
the other serotypes.  The newer approaches followed by some research groups in creating 
a vaccine against DENV are utilizing protein subunit vaccines, heterologous viral 
vectors, inactivated virion containing only structural proteins, or nucleic acid vaccines 
encoding pre-M and E proteins (1).  
A different approach, the PIV vaccine, contains all of the viral structural protein 
and RNA, since it is an inactivated wild-type virus. The inclusion of structural proteins 
allows the induction of an immune response against them. Recombinant subunit vaccines 
allow for the targeting of a specific viral antigen to induce an immune response. Most 
subunit vaccines express truncated parts of the envelope protein. Various protein 
expression systems has been used such as bacterial, yeast, insect, mammalian cells, etc. 
(17). VLP vaccines are advantageous because it does not contain any replicative gene 
material, but it is able to express a high and repetitive amount of antigens on its 
membrane. Studies have shown that this increases the immunogenicity of the vaccine. 
DNA and virus-vectored vaccines is a great design for in vivo expression of antigens; 
most are in the form of VLPs. DNA vaccines are also advantageous in their thermo-
stability, which causes it to be cost-efficient for vaccine storage and transport. Virus-
vectored vaccine may induce immune response against both the expressed DENV antigen 
as well as the viral vector itself. The utilization of a well-known and well-characterized 
licensed vaccine has been established as a vaccine vector. Some concerns have arisen, 
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however, that pre-existing immunity against the viral vector itself may halt the 
immunogenicity of the virus-vectored DENV vaccines (17, 19). All of the vaccine 
designs against DENV have its advantages and disadvantages. 
Type Vaccine approach Developer 
Stage of 
Development 
LAV, 
Tetravalent, 
Chimeric 
Chimeric viruses YFV17D-DENV Sanofi Pasteur Phase III 
LAV. 
Tetravalent, 
Chimeric 
Chimeric DENV with 3’ UTR deletion 
mutations (Δ30) 
NIH/ NIAID Phase I 
LAV, 
Tetravalent, 
Chimeric 
Empirically attenuated (passaged in 
tissue culture) Recombination using 
DENV-2 backbone and pre-M/E from 
DENV-1 to DENV-4 
CDC-Inviragen Phase II 
LAV, 
Tetravalent 
Empirically attenuated by passage in 
primary dog kidney cells (PDK) 
WRAIR/GSK Phase II 
PIV, Tetravalent 
Purified and inactivated DENV-1 to 
DENV-4 
WRAIR Phase I 
PIV, Monovalent Purified and inactivated DENV-1 WRAIR Phase I 
Recombinant 
Subunit 
E protein of DENV, affinity purified, 
produced in insect cells 
Hawaii 
Biotec/Merck 
Phase I 
Recombinant 
Subunit 
DIII of the E protein fused to a carrier 
protein 
 Preclinical 
DNA Targeting NS1 Multiple Preclinical 
DNA Tetravalent 
DENV-1 to DENV-4, pre-M and E 
proteins 
NMRC Phase I 
DNA Tetravalent 
DIII of the E protein from DENV-1 to 
DENV-4, synthetic consensus 
(SynCon
TM
) Human codon optimized 
Inovio Precilinical 
DNA 
Monovalent 
DENV-1 pre-M and E proteins NMRC Phase I 
DNA Shuffle 
E protein from DENV-1 to DENV-4, 
codon optimized DNA shuffling, 
generating single chimeric antigen 
NMRC/ Maxygen Preclinical 
Adenoviral 
Vector 
Expression of the pre-M and E proteins 
from DENV-1 to DENV-4 in 
recombinant adenoviral vector 
NMRC/GenPhar Preclinical 
Alphavirus 
replicon particles 
Expression of the pre-M and E proteins 
or soluble E dimers from DENV-1 to 
DENV-4, in VRP 
Global Vaccines Preclinical 
 
 
Table 1. Dengue Vaccine Candidates in Various Stages of Development (6). 
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1.7 Domain III as a Vaccine Target. The E protein of DENV forms a dimeric 
assembly of ninety subunits displayed in icosahedral symmetry. Each monomer contains 
three structural domains (Fig. 8): Domain I (DI), Domain II (DII) and Domain (DIII). DI 
of the E protein has an 8-stranded central β-barrel structure and two large loops that form 
the elongated DII, which has the highly conserved hydrophobic fusion peptide (20, 21). 
The C-terminal of DIII can fold independently from the other two domains in an 
immunoglobulin-like manner as a core protein, stabilized by a single conserved disulfide 
bridge (10). During the fusion transition, DIII undergoes the most significant 
displacement (20).  
DIII of the envelope protein has been known to contain a cell surface receptor 
recognition site, and in turn it is important in host cell binding. Previous studies have 
observed that recombinant DIII from the E protein of DENV have inhibited viral 
infectivity through binding competition with the host receptor (20). This suggests that 
DIII contains a neutralizing type-specific and sub complex-specific epitopes. Anti-DIII 
antibodies that have been found to be potently neutralizing and type-specific, hence less 
cross-reactive with a lower risk of causing ADE (17, 19). Although DIII displays an 
Figure 8. Structure of the Dengue E Protein with its Three Domains. A, The three domains of 
dengue E protein: DI (red), DII (yellow), and DIII (blue). B, Conformation of the E protein in the 
mature virus particle. C, Arrangement of each domain of the E protein on the surface of the mature 
virus particles; 90 dimers in an icosahedral lattice (21). 
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identical fold across all four different serotypes of DENV, it also has the most variable in 
amino acid sequences between the four serotypes (1, 20). Moreover, studies have shown 
that neutralizing serotype-specific antibodies against DENV focuses on DIII (22). 
Mutations to DIII residues have also lead to the decrease in the binding of neutralizing 
monoclonal antibodies (23). Therefore, for our project, we have decided to focus on 
DENV 2 E DIII as the antigenic epitope to target in creating our recombinant vaccine.  
1.8 Hepatitis B Virus-like Particles. Virus-like particles (VLPs) are multi-
protein complexes that are similar in structure to complete viruses, but it does not contain 
a viral genome, making them non-infectious, thus safer (1). VLPs formation is completed 
through budding from the usual cellular mechanism, which allows it to be similar to the 
infective virus structure (24). VLPs have been used in production of vaccines in the 
pharmaceutical industry due to its ability to cause a good immune system response; VLPs 
has been shown to elicit both humoral and cellular immune response (25). This is partly 
due to their highly repetitive surface proteins that form its structure, which will induce 
the activation of the immune system. Two of the well-known vaccines that have been 
developed through the use of VLPs are human papilloma virus (HPV) and hepatitis B 
virus (HBV) (24). This was done using the hepatitis B virus small surface antigen 
(HBsAg) and the VLP produced by the recombinant L1 protein of HPV. These VLPs 
induce both neutralizing and protective immune responses and has been shown to be 
stable and safe.  Hepatitis B virus creates surface antigens that make up the viral envelope 
protein. There are three different types of surface antigens that are produced: the large 
surface antigen (L), made up of preS1, preS2 and the S domain, the middle surface 
antigen (M), made up of the preS2 and the S domain, and the small surface antigen 
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(HBsAg), made up of only the S domain (26). The small surface antigen of hepatitis B 
virus (HBsAg) has been shown to be produced in the highest quantity.  In addition, 
HBsAg have been observed to spontaneously assemble to create empty VLPs in the 
absence of any other viral. The VLPs created by HBsAg is made up of 100 to 150 
subunits of the 226 amino acid of the HBsAg protein (26). Due to the small size of DIII 
of the E protein (~100 amino acids), expressing it by itself will not elicit a strong immune 
response; hence we will use chimeric VLPs as our vaccine platform (Fig. 9). Chimeric 
VLPs are an adaptation to the VLP design and structure, where the immunogenic 
antigens are incorporated onto their surface (25, 27). This will be done through the fusion 
of the target epitope to the envelope protein of a virus used to form the VLP. This process 
allows the expression of any specific epitope that is targeted by neutralizing antibodies to 
be expressed on a highly immunogenic VLP, which may act as an adjuvant and boosts 
the immune response (27, 28). As previously mentioned, purified HBsAg VLPs are used 
in the currently licensed vaccine against HBV. Antibody protection induced by this 
vaccine is mainly specific for the “a”-determinant of the viral envelope. Previous studies 
have shown the successful insertion of foreign sequences into the N-terminus of HBsAg 
without affecting the conformational epitopes of the “a”-determinant (26, 29, 30). 
Therefore, it is possible to create a chimeric HBsAg VLP to function as a bivalent 
immunogens that will induce immune response against HBV and the foreign epitope. 
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Figure 9. Illustration of the Chimeric VLPs Engineered to Express DIII and HBsAg. At the top 
is the representation of the Hepatitis B surface antigen coding sequence, breaking down the domains 
that make up the large, middle, or small surface antigens; with its respective preS1, preS2, and S 
domains. The last coding sequence represent the chimeric VLP, which includes the 101 amino acid 
of DIII fused to the N-terminus of the 226 amino acid of S domain, by a 14 amino acid long bridge. 
The bottom part of the diagram shows the native VLP produced by HBC which includes the L 
(blue), M (orange) and S (pink) antigens. To its left is the representation of the hybrid DIII-HBsAg 
VLPs, which includes the S antigen, the DIII (yellow) and the bridge (green). The chimeric VLP on 
the far left side is expected to be produced from the recombinant virus, MVvac2(DIII-S,S)P, and the 
chimeric VLP on the middle is expected to be produced by the recombinant virus MVvac2(DIII-S)N. 
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1.9 Measles Virus as Viral Vector. Measles virus (MV), a member of the 
Paramyxoviridae family, is an enveloped, negative-sense single-stranded RNA virus. The 
negative sense genome functions as template to generate sub-genomic mRNAs though a  
 
conserved mechanism (31). There are six cistrons coding for eight proteins in MV, which 
includes coding for: N, P/C/V, M, F, H, and L proteins (32, 33). The transcription 
mechanism of mononegavirales posits that boundary signals between cistrons determine 
a gradient transcription from 3’ to 5’ extremes (Fig. 10). The gene closest to the 3’ end 
(coding for N protein) is to be transcribed in higher amount and the gene towards the 5’ 
end (coding for L protein) is to be transcribed in the least amount (31, 32).   
The recognition of these sequences allows us to insert additional transcription 
units (ATUs) between native cistrons. Thus recombinant strain of MV can be created by 
various ATUs that may be placed strategically within the viral genome, generating a viral 
Figure 10. Schematic of the Transcription and Replication Mechanism of the Measles Virus 
Genome. The top image of the diagram depicts the genomic map of the measles virus genome, a 
negative sense, single-stranded RNA. The bottom image of the diagram shows the viral transcripts, 
5’-3’ mRNAs, which represent the amount of each mRNA produced due to the viral transcription 
gradient (32). This in turn will cause a gradient in the amount of proteins translated based on the 
location of the gene encoding that specific protein.  
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vector that expresses foreign proteins (34). The locations of these ATUs determine the 
amount of protein that will be produced from that inserted gene (32). Theoretically, ATU 
sites cloned after the coding region of each structural protein can be generated. 
Practically, we have available in the laboratory ATUs cloned in N-P, P-M, H-L and L-
trailer gene boundaries and some combinations; the presence of convenient restriction 
sites allows the straightforward cloning strategy.  
There are several features that make MV an attractive option as viral vector.  Its 
genome only replicates in the cytoplasm, which confirms that it will not integrate into the 
host’s cell DNA, and the attenuated strain of MV has never reversed back to 
pathogenicity, pointing at the genetic stability of MV (33). On this regard, this project 
will use MVvac2 as the viral vector, which is the equivalent to the Moraten vaccine 
strain. The attenuated MV strain (Moraten) has been in use as a vaccine for almost fifty 
years with an excellent record of safety and efficacy. The Moraten vaccine strain was 
empirically attenuated from the Edmonston wild-type MV strain. It was passaged: 24 
times in human kidney cells at 37ºC, 28 times in human amnion cells at 37ºC, 12 times in 
the intra-amniotic cavity of chick embryo at 37ºC, 16 times in chick embryo fibroblast at 
37ºC, 8 times in chick embryo fibroblast at 36ºC, and then 40 times in chick embryo 
fibroblast in 32ºC (35, 36). The summation of these passaging resulted in many 
nucleotide substitutions in the MV genome which contributes to its attenuation; the 
specific substitution that caused the attenuation is still unknown (35).  
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After a single dose (Moraten strain) the vaccine confers life-long immunity, 
showing a robust immune response, both cell mediated and neutralizing antibodies (33, 
37). In addition, a previous study on MV-vector vaccine expressing HIV envelope protein 
observed high-tittered antibodies against the expressed proteins in macaques previously 
immunized with MV. Thus, disputing the claim that revaccination with a MV-vectored 
vaccine in previously immunized individuals will reduce the immunogenicity of the 
recombinant vaccine. On the other hand, the long-term use of the vaccine strain makes a 
recombinant MV based on this vaccine vector to have an advantage economically; in 
which it can be produced on a large scale for a low cost using the production and 
distribution line for the current MV vaccine (33, 34). Various successful vaccines have 
been made through attenuated viruses, which include measles, mumps, polio, rubella, and 
yellow fever (37). It follows then that a recombinant MV as a viral vector will also be 
useful in presenting multiple viral antigens to the immune system. Therefore, we will use 
MV as a viral vector expressing our engineered hybrid DIII-HBsAg, to create the 
respective chimeric VLPs.  
1.10 Research Project Objectives and Hypothesis. Since DIII correlates with 
the serotype-specific neutralizing epitopes, this research project centers on the 
development of a vaccine platform that will display this antigenic determinant on the 
surface of subviral HBsAg particles vectored by a recombinant MV. Thus, this chimeric 
VLP engineered from the hybrid DIII-HBsAg will be expressed as an additional 
transcription unit (ATU) inserted into the MV genome. 
In this study we used HBsAg as a display scaffolding the DIII of DENV-2 that is 
only about 100 amino acids long. A previous study successfully expressed a repetitive 
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epitope from Plasmodium falciparum CS protein using an HBsAg as a carrier (38). Sixty-
four amino acids of the CS protein were fused to the N-terminus of HBsAg, followed by 
226 amino acids of the HBsAg itself. Our design followed this successful model by 
fusing the 101 amino acid of DIII of DENV-2 to the N-terminus of the 226 amino acid of 
HBsAg, using a 14 amino acid bridge (Fig. 9). Therefore, we only used the S domain of 
the HBV surface antigen fused with the DIII by the utilization of a disulfide bridge to 
generate DIII-HBsAg. This disulfide bridge will ensure the correct formation and 
independent folding for both DIII and HBsAg (Fig. 9). The generated artificial gene 
encoding for this protein was inserted into the MV genome so that the viral mechanism 
will drive the expression of this chimeric antigen. Following previous observation of 
HBsAg protein, the hybrid DIII-HBsAg is expected to self-assemble into a chimeric 
VLP. We hypothesize that the recombinant MVs will induce an immune response against 
MV, HBV, and DENV. 
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1.11 Specific Aims.  
Aim 1: Generate a recombinant, infectious cDNA containing full-length measles 
virus genome with the co-linear HBsAg and hybrid DIII-HBsAg coding sequences. An 
overlapping PCR will be done in order to create the hybrid DIII-HBsAg coding sequence. 
The ATU containing this coding sequence will be inserted after the P cistron in 
MVvac2(DIII-S,S)P and after the N cistron in MVvac2(DIII-S)N. MVvac2(DIII-S,S)P 
will also have an ATU encoding HBsAg inserted after the N cistron. We expect that the 
insertion of the ATU will allow for the successful assembly of the hybrid VLP, with 
different quantity of DIII-S transcribed due to the location of the ATU in the MV 
genome; with or without the presence of native HBsAg. 
Aim 2: Generation of recombinant viruses and analysis of their replication 
fitness. The infectious cDNA previously generated will be used to rescue the recombinant 
viruses following an established reverse genetic system. We expect to successfully rescue 
the recombinant MVs, which will follow a similar replication pattern as the parental 
strain, MVvac2.   
Aim 3: Biochemical characterization of MVvac2(DIII-S,S)P and MVvac2(DIII-
S)N. Biochemical tests done to characterize the recombinant MVs will analyze the 
expression of the hybrid DIII-S antigen and the correct formation of the hybrid VLP. We 
expect the DIII antigen to be displayed on the surface of the hybrid VLP, which will be 
successfully self-assembled, following the same characteristics as the native HBsAg 
VLP. 
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Aim 4: Immunogenicity study of recombinant viruses in measles-susceptible small 
animal model. Animal experiments will be done to analyze the immunogenicity of the 
recombinant MVs compared to the reference and parental strains. We hypothesize that 
the animal sera collected will contain neutralizing antibodies against measles, hepatitis B 
and dengue virus.   
 
 
 
 
  
 
Table 2. Outline of the Specific Steps Completed to Reach the Research Aims. 
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Chapter 2. Materials and Methods 
2.1 Cells and Viruses. Vero/hSLAM cell line (African green monkey cells which 
expresses the MV receptor, SLAM, on its surface) was used for experiments done with 
MV and recombinant MVs. These cells, courtesy of Yusuke Yanagi, were sustained with 
DMEM 5% FBS P/S, containing: Dulbecco’s Modified Eagles’s Medium with high 
glucose concentration (DMEM, Sigma-Aldrich, St. Louis, MO), 5% Fetal Bovine Serum 
(FBS, Atlanta Biologicals, Flowery Branch, GA), and 1% Penicillin-Streptomycin (P/S, 
Sigma-Aldrich, St. Louis, MO). To promote selection for the expression of SLAM, these 
cells were also supplemented with 0.5 mg/ml of G418 (Enzo Life Sciences, Farmingdale, 
NY). Helper 293-3-46 cell line, a derivative of HEK 293 cells, was used to rescue 
recombinant MVs. These cells, courtesy of Roberto Cattaneo, were sustained with 
DMEM 10% FBS P/S, and supplemented with 1.2 mg/ml of G418. BHK-21 cell line 
(Baby Hamster Kidney Fibroblast Cells) was used for experiments done with DENV-2. 
These cells were sustained with DMEM 10% FBS P/S when passaged for stock, but 
maintained in 50/50 DMEM 5% and DMEM 10% when seeded for experimental 
purposes. 
Viral stocks for MV and recombinant MVs were prepared by infecting 
Vero/hSLAM cell monolayer with a multiplicity of infection (MOI) of 0.03 and 
incubated at 37
o
C while being monitored for cytopathic effect. Infected cells were 
collected in Opti-MEM (Gibco by Life Technologies, Grand Island, NY) when it reached 
~80% cytopathic effect. Cells collected were lysed by two cycles of freeze and thaw, and 
then centrifuged to clear the supernatants, of which small aliquots will be prepared from. 
Viral aliquots are titrated and stored at -80ºC. Viral stocks for DENV-2 (ATCC, Strain 
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16681) were prepared by infecting BHK-21 cell monolayer with a MOI of 1, and 
incubated at 37ºC for a specific amount of time, 5 days. Supernatant was then collected 
and cleared when necessary, small aliquots are made, which are then titrated and stored at 
-80ºC. Opti-MEM is used to replace the media during infection for MV as wells as 
DENV-2. Two viruses were used as controls: the parental strain, MVvac2 and the 
reference strain, MVvac2(HBsAg)N (39). The (HBsAg)N control strain contains an 
HBsAg ATU after the N cistron. In one animal experiment, DENV-2 was also used as a 
control. 
2.2 Plasmid Design and Construction. Primers were designed for construction 
of an artificial gene expressing a fusion glycoprotein composed of the Domain III 
(Dengue 2) fused to HBsAg (Table 3). Primer 1 is designed as the forward primer to 
amplify DIII, it includes the coding sequence for the signal peptide of the light 
immunoglobulin chain. Primer 2 is the reverse primer to amplify DIII; it includes the 
partial formation of the coding sequence of an amino acid bridge composed of (SG3)3. 
Primer 3 is the forward primer to amplify HBsAg; it also includes a part of the 
aforementioned bridge. Primer 2 and primer 3 complementary sequence of the bridge aid 
in the overlapping PCR of the two gene sequences. Primer 4 is the reverse primer to 
amplify HBsAg and was also used as the reverse primer to amplify the final product DIII 
and HBsAg, in a similar way primer 5 is the forward primer that was used for the final 
amplification of the fused DIII-HBsAg coding sequence. 
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 Sequence 
Gene 
Amplified 
1 
5’ATTCACGCGTATGGACATGCGGGCCCCCGCCCAGATCTTCGG
CTTCCTCCTCCTCCTCTTCCCCGGCACCCGGTGCCAGCTCAAAG
GAATGTCA-3’ 
Domain III 
2 
5’TGATCCTCCTCCTGATCCTCCTCCTGAGCTAGCCTTAAACCAGTT
GAGCTTC3’ 
Domain III-
Bridge 
3 
5’GGAGGAGGATCAGGAGGAGGATCAGGAGGAGGAATGGAGAAC
ATCACATCAG3’ 
Bridge-
HBsAg 
4 5’GACGTCTTAAATGTATACCCAAAGACA3’ HBsAg 
5 5’ATTCACGCGTATGGACATGC3’ Overlapping 
 
 
 
Overlapping PCR was done to generate the hybrid DIII-S antigen coding 
sequence. First, the coding sequence of the DIII region of the envelope protein of DENV-
2 (strain 16681, pD2/IC-30P-A) was amplified by RT-PCR. This amplicon is flanked by 
a MluI restriction site at the 5’ end and the coding sequence for the light immunoglobulin 
chain signal peptide as well as the coding sequence of a 15 amino acid bridge at the 3’ 
end. Second, the coding sequence of HBsAg from pB(+)MVvac2(HBsAg)N was 
amplified by PCR. This amplicon is flanked by a complementary region to the 15 amino 
acid bridge at the 5’ end and by an AatII restriction site at the 3’ end. Both fragments 
were spliced together by overlapping PCR and the product was cloned into the shuttle 
vector pJET 1.2. 
In the first plasmid, pB(+)MVvac2(DIII-S,S)P, the DIII-S insert was cloned into 
the ATU located after the P protein (Fig. 14). The vector used as the backbone for this 
plasmid was a previously cloned pB(+)MVvac2(HBsAg)N (39). Therefore the first 
plasmid contains two ATUs, HBsAg coding sequence downstream of the N cistron and 
the hybrid DIII-HBsAg coding sequence downstream of the P cistron. To generate the 
Table 3. Primer Sequences for Overlapping PCR to Construct the Hybrid DIII-
HBsAg Coding Sequence. The italicized sequence primer 2 and primer 3 indicate the 
coding sequence for the bridge (15 amino acids) that was supplemented to link Domain III 
and HBsAg together. 
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first plasmid, a shuttle vector pUC19 was digested at SbfI and KasI restriction site; 
producing a 2.4 kb vector. The insert was also digested with SbfI and KasI restriction 
enzymes, coming from pB(+)MVvac2(HBsAg)P, producing a 4.8 kb insert. The ligation 
of these products resulted in pUC(HBsAg)P, which was confirmed by a restriction digest 
with DraI. The HBsAg coding sequence cloned in the shuttle plasmid was then swapped 
by the hybrid DIII-HBsAg coding sequence using MluI and AatII digestion; producing a 
~7 kb vector and ~600 bp insert. This ligation of this vector and insert resulted in 
pUC(DIII-S)P, which was confirmed by a restriction digest with PvuI. Then, the SbfI and 
KasI restriction fragment from pUC(DIII-S)P containing the hybrid DIII-S coding 
sequence downstream of the MV P cistron substituted the corresponding fragment in 
pB(+)MVvac2(HBsAg)N. This restriction digest produced a 17 kb vector and 4 kb insert 
(Fig. 16. A). The ligations of these digest products then resulted in the final full-length 
plasmid pB(+)MVvac2(DIII-S,S)P, which was confirmed by a restriction digest with 
HindIII (Fig. 16. B). In addition, the full-length plasmid was also sent for DNA 
sequencing, using the appropriate forward and reverse primers for MV sequencing the 
ligation boundaries, shown in table 4. 
The second plasmid, pB(+)MVvac2(DIII-S)N was constructed using a vector that 
is pB(+)MVvac2(HBsAg)N. The insert of the HBsAg gene sequence at the N position is 
then swapped with the DIII-S insert. Therefore this plasmid only has one ATU where the 
HBsAg gene sequence is fused to DIII. The vector, pB(+)MVvac2(HBsAg)N and the 
insert from pUC(DIII-S)P were both digested with MluI and AatII, producing a 20 kb 
vector and a 1 kb insert. The ligations of these digest products then resulted in the final 
full-length plasmid pB(+)MVvac2(DIII-S)N, which was confirmed by a restriction digest 
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with HindIII (Fig. 15. A). This full-length plasmid was also sent for DNA sequencing, 
using the appropriate forward and reverse primers for MV, shown in table 4. 
Plasmid Sequenced DNA Sequencing Primers Name 
pB(+)MVvac2(DIII-S,S)P 5’-AGCTGCTGAAGGAATTTC-3’ 3101F 
pB(+)MVvac2(DIII-S,S)P 5’-AGCCTGCCATCACTGTA-3’ 3548R 
pB(+)MVvac2(DIII-S)N 5’-GGCAAGAGATGGTAAGG-3’ 1201F 
pB(+)MVvac2(DIII-S)N 5’-GTTGTCTGATATTTCTGAC-3’ 1939R 
 
 
 
 
2.3 MV Reverse Genetics System. A Measles Virus reverse genetics technique 
was used to rescue the recombinant MV (Fig. 17) following the method established by 
Radecke et al. modified by Parks et al. (36, 40). Day 1: Cell culture (293-3-46) was 
seeded in a T75. After the T75 flask has become confluent, cells were split into 2 plates 
(6-wells), using PBS and trypsin (Mediatech) in a 3:1 dilution. Done using 13 mL of 
DMEM-10%FBS and plating 1 mL of cell per well plus 1 mL of fresh DMEM-10%FBS. 
Incubated for 3-5 hours (until cells are attached). Transfection of cell line was done 
through calcium phosphate precipitation using a ProFection kit (Promega, Madison, WI) 
with two plasmids, the specific MV full length genome (Recombinant MV) and the 
pEMC-La (coding for the MV polymerase protein, courtesy of R. Cattaneo). Day 2: The 
transfected cells were heat-shocked for 3 hours at 42ºC. Day 3 and 4: Vero/hSLAM cells 
were seeded in P100 plates. After cell attachments, the rescue cells were overlaid on the 
Vero/hSLAM cells to recover MV infectivity on them. The appearance of cytopathic 
effects was monitored in the following days. Once syncytia are observed, single isolated 
syncytia can be picked and propagated on Vero/hSLAM cell line.  
Table 4. Primer Sequences Used in DNA Sequencing of Full-length Recombinant 
Plasmid. To sequence pB(+)MVvac2(DIII-S,S)P, we used 3101F forward primer and 
3548R reverse primer, which means that the 3101-3578 nucleotides of the recombinant 
plasmid was sequenced. To sequence pB(+)MVvac2(DIII-S)N, we used 1201F forward 
primer and 1939R reverse primer, which means that the 1201-1939 nucleotides of the 
recombinant plasmid was sequenced.  
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 2.4 Multi-step Growth Kinetic Analysis of Recombinant MVs. Multiple-step 
growth kinetic was performed to document the replication fitness of recombinant MVs, 
MVvac2(DIII-S,S)P and MVvac2(DIII-S)N. Vero/hSLAM cells (5x10
5
 cells/well) were 
infected with a multiplicity of infection (MOI) of 0.03, in a 6-wells plate incubated at 
37ºC. Cells were scraped in 1 mL of Opti-MEM for the intracellular sample and 
supernatant for the extracellular sample was collected at 12, 24, 36, 48, 72, and 96 hours 
post-infection. Intracellular sample was lysed by a single freeze-thaw cycle at the 50% 
tissue culture infectious dose (TCID50) was assessed in Vero/hSLAM cells using the 
Spearman-Kärber end-point dilution method to verify the efficiency of the production of 
MV recombinant particles (41). The controls used were the parental strain, MVvac2, and 
the reference strain, MVvac2(HBsAg)N. 
 2.5 Titration of Viruses. Titration of MV and recombinant MVs was done by 
assessing its TCID50. Vero/hSLAM cells were seeded into 96-well plates with 2x10
4 
cells 
and 200 µl of DMEM 5% FBS P/S, per well. Plates were incubated at 37ºC for 1 hour. A 
ten-fold serial dilution is then done in a separate 96-well plate, by using 270 µl of Opti-
MEM and 30 µl of the viral prep; the serial dilution is done 12 times. The dilution is then 
transferred by adding 30 µl of each dilution in 8 repeats (8 rows of the 96-well plate). 
The plate is then incubated at 37ºC and read 3 days later. The TCID50 was calculated 
using the Spearman-Kärber end-point dilution method (41). 
 Titration of DENV-2 was done by a plaque assay using BHK-21 cells. A 24-well 
plate was seeded with 1x10
5
 cells and 500 µl of 250 µl DMEM 5% and 250 µl DMEM 
10% FBS P/S.  Plate was incubated at 37ºC for at least 4 hours to let the cells attach. 
Next, 8 series of ten-fold serial dilution is done by using 900 µl of Opti-MEM and 100 µl 
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of the viral prep. The dilutions is incubated at 37ºC for 1 hour and then 100 µl of each 
dilutions is added to the 24-well plate seeded with BHK-21 cells; this is done in 
duplicate. The 24-well plate is incubated at 37ºC for 4 hours, to allow for viral infection. 
Then 500 µl of overlay media is added to each well, which encourages the formation of 
isolate plaques. The overlay media contains: 3% carboxymethyl cellulose (CMC) made in 
100 ml of Nanopure H2o with the addition of 3 g of CMC (Sigma-Aldrich, St. Louis, 
MO), 20 ml of FBS, 2 ml of 200mM L-glutamine (Gibco by Life Technologies, Grand 
Island, NY), 200 ml of Modified Eagle’s Medium 2x (MEM, Gibco by Life 
Technologies, Grand Island, NY), and P/S (Mediatech). Plates were then incubated at 
37ºC for 5 days. Plates are developed by adding 500 µl of Naphtol Blue Black (NBB) to 
each well. NBB contains: 1 g of NBB (Sigma-Aldrich), 13.6 g of Sodium Acetate 
(Sigma-Aldrich), 60 ml of Glacial Acetic Acid (Sigma-Aldrich), and Nanopure H2o up to 
1000 ml. NBB is allowed to stain the cell for about 1 hour, then washed off by immersion 
of the plates in water.  
2.6 Expression of HBsAg. A test using the Abnova HBsAg enzyme-linked 
immunosorbent assay (ELISA) kit (Novus Biologicals, Littleton, CO) was performed to 
observe the production of HBsAg by the recombinant MV. Using the supernatant 
collected from, 6-well plates seeded with 5x10
5
 Vero/hSLAM cells, infected with a MOI 
of 0.03 of the recombinant strain, MVvac2(DIII-S,S)P or the reference strain as a control, 
MVvac2(HBsAg)N. The supernatant was collected at 24, 48, 72 and 96 hours post-
infection. These supernatants were used in the HBsAg ELISA compared to a commercial 
HBsAg standards and the included negative and positive control from the ELISA kit.  
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2.7 Preparation of Protein Extracts. To analyze the protein produced by the 
recombinant MVs, protein extracts must be prepared to analyze through a western blot. 
1x10
6
 Vero/hSLAM cells were seeded in 100-mm-diameter (p100) dishes and incubated 
at 37ºC for 2-3 hours to attach. The cells were infected with a MOI of 0.3 with one of the 
viruses of mock-infected (Non-infected sample). During infection, media was aspirated, 
and virus was added mixed in 6 ml of Opti-MEM, then incubated at 37ºC. Infection was 
stopped 2 hours later by aspirating the Opti-MEM/virus and replacing the DMEM 5% 
FBS P/S. Cell monolayer was monitored and collected when about 80% cytopathic effect 
has been reached. To collect the protein extract, the media from the plate was aspirated 
and the plate was washed with phosphate-buffered saline (PBS) 3 times. Then cells are 
lysed by adding 500µL of RSB-NP40 buffer (1.5 mM of MgCl2, 10 mM of Tris-HCl [pH 
7.5], 10 mM of NaCl, and 1% Nonidet p-40, Sigma-Aldrich, St. Louis, MO) plus 
protease inhibitors (cOmplete Mini Protease Inhibitor Tablets, Roche Diagnostics, 
Manheim, Germany). The sample was then centrifuged at 4ºC for 20 minutes at 14,000 
RPM. The supernatant containing the protein was then prepared by the addition of 6x 
SDS Page loading buffer (Laemmli buffer, Bio-Rad Laboratories, Hercules, CA) and 
denatured at 96ºC for 10 minutes. Samples stored in -30ºC if not directly used. 
2.8 Analysis of Protein Expression. The samples of protein extracts were 
separate by SDS polyacrylamide gel electrophoresis (PAGE) in a 10% acrylamide gel. 
After the gel has been run, the protein were then transferred to nitrocellulose for 
immunoblotting using a 1:1000 dilution of a rabbit polyclonal anti-HBsAg antibody 
coupled to horseradish peroxidase (HRP, OBT0990P, AbD Serotec, Raleigh, North 
Carolina, USA), and a 1:500 dilution of a mouse monoclonal anti-DIII DENV-2 
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(GTX29202, GeneTex, Irvine, California, USA). The blot was incubated in the antibody, 
anti-HBsAg-HRP, for 2 hours; a secondary is not necessary because the primary antibody 
is already conjugated to HRP. This blot was developed using a chemiluminescence kit 
(SuperSignal West Pico Chemiluminescent Substrate, Pierce Biotechnology, Rockford, 
IL). When incubating with anti-DIII DENV-2, the blot was incubated for 3 hours with the 
primary antibody. Then incubated with the anti-mouse HRP-conjugated secondary 
antibody (GE Healthcare, Little Chalfont, United Kingdom) for 1 hour. Similarly, this 
blot was developed using the chemiluminescence kit. Membranes incubated with MV 
Anti-N were incubated with a primary antibody of rabbit polyclonal Anti-N 1:10,000 
(provided by R. Cattaneo) for 1 hour and a secondary antibody of goat Anti-Rabbit-
Alkaline Phosphatase conjugated (Anti-Rabbit-AP, Thermo Fisher Scientific, Anthem, 
AZ) 1:1000 for another 1 hour. The membrane was developed by visualizing the AP 
reactivity using Western Blue Stabilized Substrate for Alkaline Phosphatase Reagent 
(Promega, Madison, WI).  
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2.9 Particle Isolation and Determination of Density. HBsAg particles isolation 
was done using a discontinuous sucrose gradient of various concentrations: 60%, 50%, 
40%, 30%, and 20% (Fig. 11). To purify the released particles, supernatants from 5x10
6
 
Vero/hSLAM cells infected with either MVvac2, MVvac2(HBsAg)N, MVvac2(DIII-
S,S)P or MVvac2(DIII-S)N were collected and clarified by centrifugation in 4ºC at 5,000 
RPM for 15 min in an SX4750 rotor. 35 ml of the clarified supernatants were pelleted by 
ultracentrifugation in 4ºC at 45,000 RPM for 18 hours in an SW28 rotor. The supernatant 
was aspirated and the pellets were re-suspended in 1 ml of TNE buffer (10 mM Tris [pH 
Figure 11. Diagram of the Ultracentrifugation of the Discontinuous Sucrose Gradient 
to Isolate VLPs. Monolayers of Vero/hSLAM cells were infected with recombinant MVs 
or controls. Supernatants from infected cells were collected and clarified in 4ºC at 5,000 
RPM for 15 min. Clarified supernatant was collected and 35 ml was placed in an 
ultracentrifugation tubes. This was ultracentrifuged in 4ºC at 45,000 RPM for 18 hrs. 
Supernatant was aspirated and the pellet containing the VLPs was re-suspended with 1 ml 
of TNE buffer containing 20% of sucrose. 5ml ultracentrifugation tubes were prepared with 
the discontinuous sucrose gradient, including: 1 ml of each TNE buffer containing the 
sucrose concentration of 60%, 50%, 40%, and 30%, from the bottom to the top of the tube 
respectively. The 1 ml of re-suspended pellet is added on top of the 30% layer. This was 
ultracentrifugated in 4ºC at 37,000 RPM for 24 hrs. Then nine fractions of 500 µl, were 
collected from the top to bottom of the equilibrated tube.    
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7.8], 100 mM NaCl, 1mM EDTA) containing 20% sucrose. The TNE Buffer was used to 
create a 60% sucrose solution that was further diluted to produce 50%, 40%, 30% and the 
20% sucrose solutions.  Polyallomer centrifuge tubes (5 ml Centrifuge Tubes, Beckman 
Coulter, Brea, CA) were prepared with the discontinuous sucrose gradient, containing 
60%, 50%, 40%, and 30% sucrose solution (1 ml each from the bottom respectively). The 
1 ml of 20% sucrose solution containing the re-suspended pellet is added as the top layer. 
The tubes of fractions were ultracentrifugated in 4ºC at 37,000 RPM for 24 hours in a 
MLS50 rotor. To determine particle density and content, 500 µL fractions were taken 
from the top to bottom layers. Fractions were weighed and their density calculated. 25 µl 
aliquots of these fractions were taken and mixed 1:1 with SDS PAGE loading buffer. 
Samples were prepared to be run in a SDS PAGE, denatured at 96ºC for 10 min. Western 
blots containing these fractions were developed by various antibodies (Fig. 22). 
2.10 Animal Experiments. Two animal experiments were performed for this 
project. The Arizona State University Institutional Animal Care and Use Committee 
sanctioned all experimental procedure. The first animal experiment was performed on 
HDD-SLAM-IFNar
KO
 transgenic mice. These mice express one of the human MV 
receptor, hSLAM, in a type I interferon deficient environment, which will allow for MV 
replication. These mice are also H2K
b
 and D
b 
knock out, which inhibits the mice MHC 
class I allele presentation restriction.  In addition, these transgenic mice also presents 
MHC class I antigenic peptides with a HLA A2.1 restriction, the most common human 
MHC class I allele, using an artificial allele termed HHD, which contains the human 2 
microglobulin fused to the HLA-A2.1 molecule where the 3 domain was substituted by 
the homologous region of murine origin. With this arrangement, the HHD molecule is 
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functionally independent of murine macroglobulin for expression and display and 
recognized by murine CD8+ T lymphocytes. 
Groups of 2 to 5 transgenic mice were vaccinated by the intraperitoneal (i.p) route 
with three doses of 5x10
5
 TCID50, including: 4 animals vaccinated with the parental 
strain, MVvac2, 5 animals vaccinated with the reference strain, MVvac2(HBsAg)N, and 
5 animals vaccinated with the recombinant strain, MVvac2(DIII-S,S)P. Two animals had 
a vaccination schedule of three doses of 1x10
5 
PFU of the control, DENV-2. However, 
these 2 animals in actuality received only 5x10
2
 PFU doses.  All of the animals were 
vaccinated at three different times, at day 0, 1 and 14 (Fig. 12). Then all of the animals 
were euthanized and exsanguinated 28 days after the last vaccination. Sera collected from 
immunized animals were separated and heat-inactivated at 56ºC for 1 hour. Aliquots of 
heat-inactivated sera were stored in -30ºC until analyzed. 
 The second animal experiment was performed on huCD46Ge-IFNar
KO
 transgenic 
mice. These mice express a different MV receptor, CD46, with human-like distribution. 
Figure 12. Diagram Representing the Vaccination Schedule Given to the HDD-SLAM-
IFNar
KO
 Transgenic Mice in the First Animal Experiment. In the first animal 
experiment, the animals received three doses at day 0, 1, and 14. Day 0 was given to induce 
the expression of the MV receptor, SLAM, since it is only expressed in activated 
lymphocytes. Day 1 is the first dose given to the animals, followed by the booster second 
dose 14 days later. All animals were exsanguinated 28 days after their last vaccination. 
Animal sera were isolated and decomplemented. (Syringe – dose given, Blood – Mice 
exsanguinated).  
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They also lacked of type I interferon pathway, which will allow for MV replication. 
These transgenic mice represent the gold standard for small animal models testing 
measles vaccine immunogenicity. These groups of mice were also vaccinated through the 
i.p. route, with one or two doses of 1x10
5
 TCID50, including: 5 animals vaccinated with 
one dose of the parental strain, MVvac2 x1, 3 animals vaccinated with two doses of the 
reference strain, MVvac2(HBsAg)N x2, 4 animals vaccinated with one dose of the 
recombinant strain, MVvac2(DIII-S,S)P x1, 7 animals vaccinated with two doses of the 
same recombinant strain, MVvac2(DIII-S,S)P x2, and 3 animals vaccinated with two 
doses of the second recombinant strain, MVvac2(DIII-S)N x1. The first dose for all of the 
animals was given on day 0. Then animals scheduled to only receive one dose of their 
vaccine were exsanguinated 28 days after the first done, whereas the animals schedule to 
receive two doses gets their booster vaccine (Fig. 13). The rest of the animals were 
exsanguinated 14 days after the second dose was given. Sera collected from immunized  
 
 
 
 
 
 
 
 
 
Figure 13. Diagram Representing the Vaccination Schedule Given to the huCD46Ge-
IFNar
KO
 Transgenic Mice in the Second Animal Experiment. In the second animal 
experiment, the animals received either one or two doses of their respective vaccine. The 
first dose was given on day 0. Then, 28 days after the first dose, those animals with a 
vaccination schedule of only 1 dose were exsanguinated: MVvac2 x1 and MVvac2(DIII-
S,S)P x1; whereas those animals with a vaccination schedule of two doses, received their 
second dose: MVvac2(HBsAg)N x2, MVvac2(DIII-S,S)P x2, and MVvac2(DIII-S)N x2. 
Then, 14 days after the second dose, the rest of the animals were exsanguinated. Animal 
sera were isolated and decomplemented. (Syringe – dose given, Blood – Mice 
Exsanguinated. 
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animals were separated and heat-inactivated at 56ºC for 1 hour. Aliquots of heat-
inactivated sera were stored in -30ºC until analyzed. 
2.11 Analysis of the Immune Response of Vaccinated Animals. The sera 
collected from each immunized mice were analyzed for its immunogenicity against all 
three viruses: measles, hepatitis B, and dengue 2. To determine MV neutralization titer, 
we performed the same experiment for sera collected from the first and second animal 
experiments. We performed serial two-fold dilutions of the sera in Opti-MEM and 
incubated with the addition of 100 TCID50 of MVvac2 at 37ºC for 1 hour. To the sera-
virus mixtures, 1x10
6 
Vero/hSLAM cells were added for every 96-well plate. These 
plates were then incubated at 37ºC for three days. Cytopathic effect of MV was 
monitored, and the neutralization titer was determined to be the highest dilution of serum 
that is still capable to cause complete neutralization of MVvac2 infectivity. 
Neutralization titer was recorded from an average of this experiment done in triplicates.  
To determine the anti-HBsAg titer in both animal experiments, we used a 
commercial species-independent quantitative ELISA kit (Alpha Diagnostic Intl. Inc., San 
Antonio, Texas, USA). The anti-HBsAg titer was recorded in milli-international units per 
milliliter by comparison with the standards from the World Health Organization that was 
supplied by the manufacturer; these standards were included in the concentrations of: 20, 
40, 80, and 160 mIU/ml. The anti-HBsAg antibody titer was recorded from an average of 
two readings for each sample done in this experiment. 
The immunogenicity studies done against DENV-2 were done different in the first 
animal experiment compared to the second animal experiment. In the first animal 
experiment, a homemade ELISA was performed to test the reactivity of the collected sera 
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against DENV-2. This ELISA, however, was not quantitative. On a 96-well plate, whole 
DENV-2 was adsorbed to the bottom of the well overnight at 4ºC; each well contained 
10
3
 PFU of DENV-2 in 100 µl of PBS TWEEN 20 0.05%. Next, all mixture in each well 
is aspirated and 150 µl of the blocking solution, PBS TWEEN 20 0.05% containing 5% 
milk (Biorad, Bio-Rad Laboratories, Hercules, CA); then incubated at 37ºC for 1 hour. 
Wells were washed three times with PBS TWEEN 20 0.05%. Sera samples diluted 1:50 
in 100 µl were added, and plates were again incubated at 37ºC for 1 hour; then wells were 
washed three times. An anti-mouse antibody added (1:2500), 100 µl to each well, then 
plates were incubated for at 37ºC for 30 min. Wells were again washed three times, and 
developed with HRP and 3M TMB-H2SO4 (tetramethylbenzemidine, Sigma-Aldrich, St. 
Louis, MO). The plates were then read at OD450. 
In the second animal experiment, the immunogenicity study against DENV-2 was 
done in two different approaches. In the first experiment, 10
5
 PFU of DENV-2 were 
mixed with heat-inactivated sera that are dilution 1:5 in 200 µl of Opti-MEM, and 
incubated at 37ºC for 1 hour. Infectivity of DENV-2 remaining after sera neutralization 
was determined through a DENV-2 plaque assay in BHK-21 cells. In 96-well plate, ten-
fold serial dilutions of the virus/sera mixtures were done using Opti-MEM. A 24-well 
plate seeded with 1x10
5
 cells per well in 500 µl of 50/50 DMEM 5% and DMEM 10% 
FBS P/S was incubated at 37ºC for 2-4 hours to allow the cells to attach. Dilutions done 
in Opti-MEM was then added to the 24-well plate, 100 µl of each dilution, and incubated 
at 37ºC for 4 hours. Next, 500 µl of the overlay media, 3% CMC, was added to each well, 
and these plates were incubated at 37ºC for 5 days. The plates were developed by 
aspirating each well and adding 500 µl of NBB, which fixed and stained the monolayer 
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of cells with acetic acid/napthol blue-black. The neutralization index was recorded as the 
logarithmic difference between the average DENV-2 titers when incubated with the 
control sera: sera collected from animals vaccinated with MVvac2, MVvac2(HBsAg)N, 
and previously obtained pre-immune sera; and the average DENV-2 titers when 
incubated with the experimental sera: sera collected from animals vaccinated with 
MVvac2(DIII-S,S)P and MVvac2(DIII-S)N. The determined anti-DENV-2 neutralization 
index is recorded on as log10NI. The second experiment performed to analyze the sera’s 
immunogenicity against DENV-2 was the classis 50% plaque reduction neutralization 
assay (PRNT50) using pooled sera from each experimental group of mice. 200 PFU of 
DENV-2 were mixed with a series of two-fold serial dilutions (1:5 to 1:320) of each 
pooled sera. This virus/sera mixture was incubated at 37ºC for 1 hour. Infectivity of 
DENV-2 remaining after sera neutralization was determined through a DENV-2 plaque 
assay in BHK-21 cells as described for the previous experiment. The neutralization titer 
was determined at the dilution that had a 50% reduction in the amount of plaques formed, 
compared to the control samples. 
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Chapter 3. Results 
 3.1 Plasmid Construction and MV Rescue. For this project, I aimed to generate 
two types of recombinant plasmids, the full length infectious cDNA plasmids are termed 
pB(+)MVvac2(DIII-S,S)P and pB(+)Mvvac2(DIII-S)N. The basic chimeric gene that all 
of these recombinants have in common is composed by the fusion of four elements (Fig. 
14). At the amino terminus is the light immunoglobulin chain signal peptide, which is a 
stretch of 22 amino acids peptide (MDMRAPAQIFGFLLLLFPGTRC), to direct the 
synthesis of our chimeric protein to the endoplasmic reticulum. Then followed by 101 
amino acids of the DIII of the DENV-2 envelope protein, a 14 amino acid bridge that is 
composed of the sequence (SG3)3 with a predicted α-helical structure. This bridge is 
important in allowing the independent folding of the DIII and HBsAg coding sequence 
that is located at the carboxyl terminus of this construction. The hybrid glycoprotein is 
Figure 14. The Genomic Map of the Recombinant MV Generated. The top diagram 
represents pB(+)MVvac2(DIII-S,S)P containing the HBsAg ATU after the N cistron and 
the hybrid DIII-S ATU after the P cistron. The bottom diagram represents 
pB(+)MVvac2(DIII-S)N containing only the DIII-S ATU after the N cistron.   
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expressed from either of two different loci in MV, downstream the N gene and 
downstream the P gene, in addition to this insertion, pB(+)MVvac2(DIII-S,S)P contains a 
separate unmodified HBsAg coding sequence cloned downstream the N gene (Fig. 14). 
In figure 16 A, the insert and vector is obtained from the SbfI and KasI restriction 
fragments of pUC(DIII-S)P containing the hybrid DIII-S insert (4 kb), and of 
pB(+)MVvac2(HBsAg)N containing the vector (17 kb), which has the additional HBsAg 
ATU independently inserted after the N cistron. In Figure 15 and 16, we confirmed the 
identity of our candidate plasmids through a restriction digest using HindIII. We were 
able to observe the expected DNA band size in our experimental samples for both 
plasmids. In addition, we further corroborated the accuracy of our insertion by DNA 
sequencing of the gene boundaries.  
Figure 15. Diagram of the Confirmation Digest for the Recombinant Plasmid 
pB(+)MVvac2(DIII-S)N. A, a diagram of the agarose gel containing samples of the full 
length pB(+)MVvac2 (DIII-S)N digested by HindIII restriction enzyme. Clone 1-4 was too 
low in concentration that nothing can be seen. However, clone 5 shows the correct pattern 
of bands that are expected. B, shows the expected bands from a HindIII digestion of 
pB(+)MVvac2(DIII-S)N.   
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Figure 16. Diagram of the Confirmation Digest for the Recombinant Plasmid 
pB(+)MVvac2(DIII-S,S)P. A, a diagram of the agarose gel containing the digested and 
purified insert, hybrid DIII-HBsAg, and the vector, pB(+)MVvac2(HBsAg)N, at the 
expected size of 4,000bp and 17,000bp respectively. B, a diagram of the agarose gel 
containing samples of the full length pB(+)MVvac2 (DIII-S,S)P digested by HindIII 
restriction enzyme; showing all 3 clones. C, shows the expected bands from a HindIII 
digestion of pB(+)MVvac2(DIII-S,S)P.  
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3.2 Reverse Genetics System in MV Rescue. Using the full-length cDNA 
construction plasmids, we rescued the corresponding recombinant viruses, termed 
MVvac2(DIII-S,S)P and MVvac2(DIII-S)N, using an established reverse genetic system 
(Fig. 17). Helper cells (293-3-46), a strain from the HEK 293 cell line that is stably 
transfected with the N and P protein of MV as well as the T7 polymerase, were 
transfected with two plasmids. One plasmid encodes the full-length recombinant 
MVvac2, pB(+)MVvac2(DIII-S,S)P and pB(+)MVvac2(DIII-S)N, with a T7 promoter. 
The second plasmid, pEMC-LA, encodes the L protein of MV which is the viral RdRp; 
this construct also have a T7 promoter, as well as an internal ribosome entry site (IRES) 
before the L gene to ensure its translation. After transfection, the full-length MV genome 
will be transcribed by the T7 polymerase into full-length antigenomic RNA, and then the 
N and P protein expressed in the helper cell will bind to form the RNP complex. The MV 
RdRp produced from pEMC-LA will then bind to the RNP complex and replicate the MV 
genome. The MV genome in a RNP complex will be transcribed, which leads to the 
generation and expression of the viral mRNAs into viral proteins following its 
transcription gradient. This will result in virion assembly and release from the infected 
host cell (40, 42). The next step was to take helper cells and overlaid it on a monolayer of 
Vero/hSLAM cells, which was then monitored for syncytia. Plaque cloning was then 
performed by picking a single-isolated syncytia and infecting a new monolayer of 
Vero/hSLAM, ensuring a pure viral stock that originated from one clone of the virus. The 
virus was then amplified to generate viral prep made from multiple passages of the MV 
that was rescued.  
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Measles infectivity generated after transfection of helper cells was amplified 
using plates of Vero/hSLAM cells with negative (non-transfected rescue cells) and 
positive controls (transfected with a control plasmid). Vero/hSLAM cells were monitored 
for cytopathic effects (CPE). Similar sizes of syncytia foci were observed for both the 
positive control and the recombinant MVs. This demonstrates that virus was indeed 
produced from the cDNA of the recombinant pB(+)MVvac2(DIII-S,S)P (Fig.17), 
initially. Hence, the insertion of two ATUs into MVvac2 did not disturb the replication of 
the virus. In addition, the green fluorescence marker on the positive control proves that 
the syncytium depicted on the bottom image in figure 17 is caused by the recombinant 
virus; in contrast to our recombinant, whose syncytia were not fluorescent. Hence, the 
second recombinant virus, MVvac2(DIII-S)N was rescued following the same procedure.  
Figure 17. Generation of a Recombinant MV using the Reverse Genetics System. A 
helper cell line (293-3-46) was transfected with the recombinant MV cDNA and pEMC-La 
(codes for polymerase). Transcription and translation will progress in helper cells, which 
will result in the assembly of new virion. The helper cells and the virion were over-laid on 
vero/hSLAM cells (38). The growth of syncytia was observed. The top image depicts the 
syncytia formed by MVGreen, a positive control. The bottom image depicts the syncytia 
formed by pB(+)MVvac2(DIII-S,S)P. The microbars in the images are 400µm.  
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After the recovery of each recombinant virus was completed, they were amplified 
and titered. The stock of MVvac2(DIII-S,S)P reached a titer of 1.8x10
5
 TCID50/ml, which 
is approximately ten times lower than the titer of the parental MV. Whereas the titer of 
MVvac2(DIII-S)N reached 5.6x10
7
 TCID50/ml, which is comparable to the parental MV. 
Overall, the creation of the recombinant plasmids and the rescue of each recombinant 
virus were deemed successful, due to the generation of the viral stock with a viable titer 
for animal experimentation. However, the next step will be to observe the replication 
fitness of each virus. 
3.3 Multi-step Growth Kinetics. To evaluate the replication fitness of the 
recombinant MV, a multi-step growth kinetics was performed in Vero/hSLAM cells 
using passage 1 of the viral stock. Cells in a monolayer (5x10
5
 cells/well) were infected 
with a MOI of 0.03. Cell-associated viral progeny were collected at different time points 
from the intracellular fraction, which includes 12h, 24h, 36h, 48h, 72h, and 96h post-
infection. These fractions were later quantified by its infectivity determined as TCID50. 
The controls used in this experiment were the parental strain MVvac2, and the reference 
strain MVvac2(HBsAg)N, a virus that expresses the HBsAg protein from downstream the 
N position.  
Shown in figure 18, the intracellular viral growth for MVvac2(DIII-S)N peaked at 
36 hours post-infection and reached a titer of around 10
7
 TCID50/ml. Whereas 
MVvac2(DIII-S,S)P peaked at 48 hours post-infection and reached a titer of around 10
5.15
 
TCID50/ml, which is about 22 to 50 times lower than MVvac2(DIII-S)N. This indicated 
that the insertion of two ATUs in MVvac2(DIII-S,S)P had a significant impact on its  
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replication fitness; compared to MVvac2(DIII-S)N, which only contains one ATU, hence 
following a similar replication fitness as the parental strain, MVvac2, as well as the 
reference strain, MVvac2(HBsAg)N, which reached a titer of around 10
7
 TCID50/ml at its 
peak. However, despite the observed significant negative effect on viral fitness, we were 
able to create a stock of each of the recombinant viruses that reached a viable 10
6
 
TCID50/ml, which was used for further experiments. The results shown in figure 18 
represents the averages of three growth kinetic experiments performed independently of 
each other.  
Figure 18. Multi-step Growth Kinetics of Recombinant MVs. Quantification of viral 
titers from cell-associated MV produced in Vero/hSLAM at specific time points post-
infection (12h, 24h, 36h, 48h, 72h, and 96h). Cells were infected with either the parental 
strain MVvac2 represented by the black line or diamonds, the reference strain 
MVvac2(HBsAg)N represented by the red line or squares, the recombinant strain 
MVvac2(DIII-S)N represented by the blue line or circles or MVvac2(DIII-S,S)P 
represented by the green line or triangles. This data is an average of three independent 
experiments, with the error bars indicating the standard deviation for each average.   
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3.4 Production of HBsAg Detected by ELISA. An initial qualitative ELISA 
specific for HBsAg was performed to demonstrate the expression of HBsAg by the 
recombinant virus, MVvac2(DIII-S,S)P. Supernatants from infected cells were collected 
at different time-points (24h, 48h, 72h, and 96h post-infection) and analyzed. As a 
control, supernatant from cells infected with the reference strain MVvac2(HBsAg)N was  
 
collected in parallel. A concentration curve using HBsAg standards was prepared for the 
ELISA. All of the samples from the infected media were positive for HBsAg since their 
readings were well above the background value (interrupted horizontal line) 
demonstrating that the antigen is being secreted upon infection (Fig. 19). Nevertheless, 
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Figure 19. Identification of Secreted HBsAg by Recombinant MVs. MVvac2(DIIIS-S)P 
secretes HBsAg upon infection. An ELISA was performed to demonstrate the expression of 
the antigen used as platform to display Domain III. Positive (+) and negative (-) controls 
validate the experiment and set up the cut-off value (interrupted horizontal line) 
Supernatants from infected cells were obtained at different time points (the virus is 
indicated, solid triangles indicate 24h, 48h, 72h and 96h post-infection) and run in parallel 
with progressive dilutions of a HBsAg standards (empty triangle indicated a progressive 
concentration of 2.5, 5, 10 and 50 ng/ml) each sample was run in duplicate in one ELISA 
experiment, the average value is shown.   
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readings of our standard curve demonstrated that this assay is only qualitative; we could 
not demonstrate any linearity of the OD450 readout. However it is important to note that 
the sensitivity of the assay is well below the lowest concentration tested (2.5 ng/ml). 
Therefore, after we were able to initially see the production of HBsAg from one of our 
recombinant viruses, MVvac2(DIII-S,S)P, we move forward in characterizing both of our 
recombinant viruses by performing more quantitative and detailed experiments. 
3.5 Characterization of the Expression of Hybrid DIII-HBsAg Antigens from 
MVvac2(DIII-S,S)P. The intracellular viral particles from Vero/hSLAM cells infected 
with a MOI of 0.5 with either MVvac2, MVvac2(HBsAg)N, or MVvac2(DIII-S,S)P were 
collected. Each infected cell monolayer were lysed at 24h post-infection; non-infected 
cells grown in a monolayer under similar conditions as the infected cells was also lysed 
and used as a control. 
 Each cell extracts was analyzed for the incorporation of DIII into the HBsAg 
VLP by an anti-HBsAg western blot under non-reducing condition (Fig. 20). A doublet, 
two bands of HBsAg were observed by the anti-HBsAg antibodies in the cell extracts 
obtained from MVvac2(HBsAg)N, the positive control. The top and bottom bands are 
glycosylated and non-glycosylated isoforms of HBsAg, respectively, observed at 
theoretical molecular weight of 27 and 24 kDA as expected. The double bands are also 
seen in the cell extract collected from the recombinant virus MVvac2(DIII-S,S)P (Fig. 
20). However, in addition to the expected doublet, we also observed another upwardly 
shifted double bands at 37 and 34 kDa; the corresponding theoretical molecular weight of 
the glycosylated and non-glycosylated isoforms of the hybrid DIII-S antigen. As 
expected, there were no observed binding of the anti-HBsAg antibodies in the samples 
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from the non-infected and MVvac2 cell extracts, used as negative controls. Overall, in 
figure 20, the upward shift of the double bands observed in the MVvac2(DIII-S,S)P cell 
extracts, shows the successful expression of DIII-HBsAg. 
 
 
 
Figure 20. Western Blots Analyzing the Expression of Hybrid DIII-S. Western blot of a 
membrane containing 4 samples, the controls, non-infected, MVvac2, MVvac2(HBsAg)N 
and the recombinant virus, MVvac2(DIII-S,S)P . The top membrane was incubated with 
anti-HBsAg antibodies. The double bands observed in MVvac2(HBsAg)N shows the 
glycosylated (top) and non-glycosylated (bottom) bands, shown by the arrows. The upward 
shift of the double bands in MVvac2(DIII-S,S)P shown by the arrowheads, represent the 
expression of DIII by HBsAg. The bottom membrane was incubated with measles antibody 
against the N protein to corroborate equal amount of the samples are represented. 
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In order to corroborate that the same amount of sample was analyzed for each cell 
extracts, a second western blot was performed. Figure 20 shows a second diagram 
(bottom) which displays the western blot results using anti-N antibodies from MV; 
everything else other than the antibodies used, was run under the same conditions as the 
previous western blot. In this western blot, we observed the same amount of N protein 
present in each of the infected cell extracts. 
3.6 Characterization of the Expression of Hybrid DIII-HBsAg Antigens from 
MVvac2(DIII-S)N and the Correct Display of DIII. After confirming the successful 
expression of the hybrid DIII-HBsAg antigen from the first recombinant virus, 
MVvac2(DIII-S,S)P, the experiment was repeated with the second recombinant virus, 
MVvac2(DIII-S)N. Lysates from Vero/hSLAM cells infected with a MOI of 0.5 with 
either MVvac2, MVvac2(HBsAg)N, MVvac2(DIII-S,S)P, or MVvac2(DIII-S)N were 
collected. Each infected cell monolayer was lysed at 24h post-infection. Each cell 
extracts was analyzed for the incorporation of DIII into the HBsAg VLP by an anti-
HBsAg western blot under non-reducing condition (Fig. 21). A doublet was observed 
similar to the previous western blot, where two bands of HBsAg, the glycosylated 
isoform at 27 kDA and non-glycosylated isoform at 24 kDa, were observed by the anti-
HBsAg antibodies in the cell extracts obtained from MVvac2(HBsAg)N, the positive 
control. In figure 21, the double bands and the upshifted doublet are also seen again in the 
sample containing MVvac2(DIII-S,S)P cell extract, as seen in the previous western blot 
(Fig. 20). Furthermore, between the two shifted double bands, the band corresponding to 
the non-glycosylated isoform, seen at 34 kDa, gives a much weaker signal than the band 
corresponding to the glycosylated isoform seen at 37 kDa. However, both of the bands 
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that were shifter upward does seem weaker than the two original doublet at 24 kDa and 
27 kDa, possibly due to the amount of the hybrid DIII-HBsAg antigen that is actually 
being produced. 
 
 
 
On the other hand, in the sample containing the MVvac2(DIII-S)N cell extract, 
we were not able to observe any binding of the monoclonal antibody. Since the western 
blot was incubated with anti-HBsAg antibody, this shows that the antibodies were not 
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Figure 21. Analysis of Successful Expression of the Hybrid DIII-S Antigen in Cell 
Lysates from Controls and Recombinant MV Infected Cells. A, samples run under non-
reducing conditions in a SDS-PAGE, western blot developed using a monoclonal antibody, 
anti-HBsAg (the S antigen); the molecular weight of the two forms of S are shown to the 
left and the molecular weight of the hybrid DIII-S to the right. The asterisk indicates 
glycosylated forms of HBsAg. B, samples run under non-reducing conditions in a SDS-
PAGE, western blot developed using a monoclonal antibody specific for dengue envelope 
protein domain III. The double bands were observed at 37 kDa and 34 kDa  
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able to detect the proteins present in the cell extract, possibly due to some changes that 
happened in the protein’s folding pattern. 
In order to analyze if the hybrid DIII-S antigen is displaying the correct DENV-2 
epitopes present in DIII. We developed a western blot using antibodies specific for 
DENV-2 DIII. This was done under reducing conditions. We were able to observe two 
bands from both of our recombinant viruses. These two bands were seen at about 37 kDa 
and 34 kDa, corresponding to the glycosylation isoforms of the hybrid DIII-S previously 
seen in the western blot developed with anti-HBsAg (Fig. 21). However, the double 
bands observed from the sample containing cell extracts from MVvac2(DIII-S)N, were 
weaker than the bands observed from the samples containing cell extracts from 
MVvac2(DIII-S,S)P.  
3.7 Particle Isolation and Characterization. The particle isolation experiment 
was performed to see the presence of hybrid VLPs in the supernatants of Vero/hSLAM 
cells infected with MVvac2(DIII-S,S)P. Figure 11 illustrate the procedure, where nine 
fractions were collected from the discontinuous sucrose gradient ultracentrifugation in 
order to confirm the expected density of the HBsAg particles, including the hybrid 
particles expressing DIII. These fractions were then loaded onto a SDS-PAGE under non-
reducing condition. The western blot was developed with anti-HBsAg monoclonal 
antibodies. The HBsAg particles were observed in fractions 4 to 6 as shown by the 
double bands in both the control sample, fractions from the reference strain 
MVvac2(HBsAg)N and the experimental sample, fractions from the recombinant strain 
MVvac2(DIII-S,S)P (Fig. 22. B). In addition, we were able to observe again the upward 
shifted double bands (shown by arrows) that correspond to the glycosylated and non-
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glycosylated isoforms of the hybrid DIII-S antigen (Fig. 22. B). These bands were 
detected in similar sucrose density (1.10-1.12g/mL, fraction 4 and 5) to the sucrose 
density of the native HBsAg secreted in the supernatants of MVvac2(HBsAg)N, the 
control (Fig. 22. A). Showing that the characteristics of the hybrid VLP secreted by 
MVvac2(DIII-S,S)P are similar to the native VLP secreted MVvac2(HBsAg)N.  
Supernatant of Vero/hSLAM cells infected with MVvac2(DIII-S)N was analyzed 
in this experiment (not shown). Since we have observed a lack of binding of the anti-
HBsAg monoclonal antibody (Fig. 21), we conclude that performing this western blot 
using the fractions from MVvac2(DIII-S)N will not be successful. We concluded that we 
might be able to detect the presence of hybrid DIII-S antigen by developing the western 
blot using the monoclonal antibody against DENV-2 DIII. However, we were not able to 
observe any binding of the antibodies in this western blot. Overall, we observed the 
presence of the hybrid DIII-S antigen in the fractions collected from supernatants of cells 
infected by MVvac(DIII-S,S)P.  
The last western blot we performed using fractions collected from the particle 
isolation is developed using antibodies against the N protein of MV. This western blot 
used the fractions collected from the supernatant of cells infected with MVvac2(DIII-
S,)P. We were able to observe that the MV particles migrated to fraction 6 to 9 based on  
the presence of the MV N protein shown on the bottom panel (Fig. 22). The fractions 
where the MV particles are located in are (fractions 6 to 9) clearly separate from the 
fractions where the native HBsAg VLP or hybrid DIII-S VLP are located in (mainly 
fractions 4 to 5). This demonstrated that the hybrid particle is incorporated separately 
from the MV particle, which migrates to the more dense fractions.  
60 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22. Particle Isolation by Discontinuous Sucrose Gradient and Analysis of Each 
Fractions Collected. Particle isolation diagrams from supernatants of Vero/hSLAM cells infected 
with either MVvac2(HBsAg)N or MVvac2(DIII-S,S)P. Supernatants were collected at 72h post-
infection and clarified. Particulate material was then pelleted and resuspended in 20% sucrose 
solution, loaded onto the 30%-60% sucrose gradient, then centrifuged to equilibrium. Nine fractions 
were collected from the top (fraction 1) to the bottom (fraction 9) in 500µL aliquots. A, Each 
fractions were weighed to determine its density. The graphic plot shows a density gradient profile 
obtained from a representative experiment. The density of each fraction is shown by the graph at the 
top in g/mL. B, Fraction samples were run in a 12.5% SDS-PAGE. The antigenic reactivity of each 
fraction was analyzed by a western blot using an anti-HBsAg antibody (top two panels) and an anti-
MV N antibody (lower panel). The top and bottom panels are depicting western blots using fractions 
from MVvac2(DIII-S,S)P infected cells. The middle panel is depicting a western blot using fractions 
from MVvac2(HBsAg)N infected cells. The hybrid DIII-S incorporate into the VLP is particle is 
shown by the arrows in the top panel. These double bands corresponding to the glycosylated and 
non-glycosylated isoforms of the hybrid DIII-S antigen can be seen at 37 kDa and 34 kDA, 
respectively.  
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Overall, we were able to confirm the incorporation of the hybrid DIII-S antigen 
on a scaffold of HBsAg, without affecting its density or the assembly of MV virion. 
3.8 Immunogenicity Study. We performed two sets of immunogenicity study 
from two different animal experiments in order to analyze the immune response that will 
be induced by our recombinant viruses. The first animal experiment was done using MV 
susceptible transgenic mice HDD-SLAM-IFNar
KO
.  These mice express one of the 
human MV receptor, hSLAM, in a type I interferon inactivated environment, which will 
allow for MV replication. These mice are also H2Kb and Db knock out, which inhibits 
the mice MHC class I allele presentation restriction.  In addition, these transgenic mice 
also presents MHC class I antigenic peptides with a HLA A2.1 restriction, the most 
common human MHC class I allele. Four viruses were used in vaccinating these mice, 
including: MVvac2, MVvac2(HBsAg)N, MVvac2(DIII-S,S)P, and DENV-2; for the 
initial animal experiment, we have decided to analyze only one of our recombinant 
viruses first. Groups of 2 to 5 animals received two doses through the intraperitoneal 
route. The doses given were 10
5
 TCID50 for MVvac2, MVvac2(HBsAg)N, and 
MVvac2(DIII-S,S)P. The doses given for DENV-2 were theoretically calculated to be 10
5
 
PFU, however the viral prep was later found to be of lower concentration; hence the dose 
given to the animal were only 10
2
 PFU. All of the animals were vaccinated at three 
different times, at day 0, 1 and 14. Then all of the animals were euthanized and 
exsanguinated 28 days after the last vaccination. The vaccination at day 0 was given to 
induce expression of the MV receptor, SLAM, because it is only expressed in activated 
lymphocytes. Isolated and decomplemented sera were used in the immunogenicity 
experiments. 
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To analyze the measles immunogenicity, we performed a micro-neutralization 
assay, there the neutralization titer represents a 90% inhibition of MV cytopathic effect in 
Vero/hSLAM cells (Fig. 23. A). As shown in figure 23, all of the animals vaccinated with 
MVvac2, MVvac2(HBsAg)N, and MVvac2(DIII-S,S)P showed responsiveness of their 
immune system to the antigenic stimulus, present in the viral vector backbone for the 
reference strain and our recombinant strain. However, we observed a four-fold reduction 
in measles immunogenicity in MVvac2(DIII-S,S)P when it is compared to the parental 
strain, MVvac2. It is possible that the insertion of 2 ATUs, resulting in the reduced viral 
fitness observed in vitro may be responsible for the difference in immunogenicity. We 
also observed a smaller reduction in measles immunogenicity in mice vaccinated with the 
reference strain MVvac2(HBsAg)N, which have an insertion of only 1 ATU. We 
determined an anti-MV neutralization titer of about 1:1000 for MVvac2, 1:640 for 
MVvac2(HBsAg)N, and 1:250for MVvac2(DIII-S,S)P. As expected, measles 
immunogenicity in sera from animals vaccinated with DENV-2 was non-existent.   
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Figure 23. Immunogenicity Study against MV, Hepatitis B and DENV-2. Immunogenicity of 
recombinant MV vectors expressing hybrid DIII-HBsAg in HDD-SLAM-IFNar
KO
 genetically 
modified mice. Groups of animals received two doses of 10
5
 TCID50 or 10
2
 PFU of DENV-2 through 
the intraperitoneal route (see material and methods for details). At 28 days after the last dose, all of 
the animals were exsanguinated. Serum was isolated and decomplemented, prepared to be used in 
neutralization assay and ELISA. Each mice is represented by one symbol and the group average is 
represented by the horizontal line. A, Results of the measles immunogenicity study, determining 
anti-MV neutralization. Y-axis scale represents the reciprocal of neutralization titer against MV. B, 
Results of the HBsAg ELISA, determining anti-HBsAg titer. Y-axis scale represents the anti-HBsAg 
titer in mIU/ml. The horizontal dashed line indicated detection level (DL) of the ELISA, this value 
was calculated from the reading of the standards and the control samples. The hepatitis b protective 
titer has been previously determined to be 10 mIU/ml. C, Results of the DENV-2 ELISA, 
determining anti-DENV-2 reactivity. Y-axis scale represents the anti-DENV-2 reactivity read under 
OD450. 
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To analyze the anti-HBsAg reactivity of the sera samples, we used a commercial 
ELISA kit. We compared the readings from each sera collected from our animals, to a 
standard curve constructed with an international reference. The known hepatitis B 
protective titer is 10 mIU/ml and the detection level of our ELISA results is shown as DL 
(Fig. 23. B). As expected, there was no reactivity detected in sera collected from mice 
vaccinated with MVvac2 and DENV-2. We observed that the anti-HBsAg titer for both 
MVvac2(HBsAg)N and MVvac2(DIII-S,S)P passed the protective titer of 10 mIU/ml. 
However, the sera collected from mice vaccinated with MVvac2(DIII-S,S)P showed an 
eight-fold reduction in HBsAg immunogenicity when compared to MVvac2(HBsAg)N. 
To analyze the anti-DENV-2 reactivity of our sera samples, we used an ELISA. 
Whole dengue 2 viruses was adsorbed to the bottom of the well overnight at 4ºC. After 
blocking, 1:50 serum dilutions were added and incubated. We used anti-mouse-HRP to 
bind to the left-over antibodies which reacted with DENV-2, and developed the plate 
with HRP and 3M TMB-H2SO4. Anti-DENV2 reactivity was only seen in two sera 
samples from animals vaccinated with MVvac2(DIII-S,S)P (Fig. 23. C). These two sera 
samples were also the samples that showed the highest measles and hepatitis B 
immunogenicity from the MVvac2(DIII-S,S)P vaccinated group. As expected, all of the 
mice vaccinated with MVvac2 and MVvac2(HBsAg)N did not show any reactivity to 
DENV-2. However, we were also not able to observe any reactivity in sera from animal 
vaccinated with DENV-2, which is supposed to be the positive control. This might have 
been caused by the error found in the doses given during vaccination of these mice, 
which happened to be much lower than previously determined. Overall, we saw reactivity 
against DENV-2 from sera collected from our vaccinated animals, but an ELISA does not 
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show protection. Protective titer will need to be determined by a neutralization assay for 
DENV-2. 
In the second animal experiment that we completed, we used a different line of 
transgenic mice. Groups of huCD46Ge-IFNar
KO
 genetically modified mice were 
vaccinated with either one dose or two doses (shown by x1 and x2, respectively) of 
MVvac2, MVvac2(HBsAg)N, MVvac2(DIII-S,S)P, or MVvac2(DIII-S)N (Fig. 24). 
These mice express a different MV receptor, CD46, with human-like distribution. They 
also have inhibition of type I interferon, which will allow for MV replication. These 
transgenic mice represent the gold standard for small animal models testing measles 
vaccine immunogenicity. Groups of 3 to 7 animals received doses of 10
5
 TCID50 through 
the intraperitoneal route. At 28 days after the first dose were given, animals scheduled to 
receive one dose of vaccination were exsanguinated, whereas animals scheduled to 
receive two doses of vaccination were given their second dose. Then 14 days after the 
second dose, these animals were exsanguinated. Sera collected from these animals were 
isosolated and de-complemented as before.                      
To analyze the measles immunogenicity from the collected sera, we performed a 
micro-neutralization assay where the neutralization titer represents a 90% inhibition of 
MV cytopathic effect in Vero/hSLAM cells. All of the animals receiving the recombinant 
viruses in this experiment showed reactivity to the antigenic stimulus created by the viral 
vector backbone. The parental strain MVvac2 showed an average anti-MV neutralization 
titer of 1:1000, which is expected from the positive control. In addition, animal 
vaccinated with the reference strain, MVvac2(HBsAg)N, showed an average anti-MV 
neutralization titer of 1:2560. However, this neutralization titer is expectedly higher 
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because these mice received two doses. The sera sample from mice vaccinated with one 
dose of MVvac2(DIII-S,S)P showed an average anti-MV neutralization titer of 1:640, 
which is lower than the samples from the mice vaccinated with the parental strain. 
However, the sera from the mice that received two doses of MVvac2(DIII-S,S)P showed 
an average anti-MV neutralization titer of 1:1280, which reached a titer higher than those 
Figure 24. Immunogenicity Study against MV and DENV-2. Immunogenicity of 
recombinant MV vectors expressing hybrid DIII-HBsAg in huCD46Ge-IFNar
KO
 genetically 
modified mice. Groups of animals received one (x 1) or two (x 2)doses of 10
5
 TCID50 
through the intraperitoneal route (see material and methods for details). At 28 days after the 
first dose, mice scheduled to receive only one dose were exsanguinated and mice scheduled 
to receive two doses were given their second dose. At 14 days after the second dose, the rest 
of the animals were exsanguinated. Serum was isolated and decomplemented, prepared to 
be used in neutralization assays and ELISA. Each mice is represented by one symbol and 
the group average is represented by the horizontal line. A, Results of the measles 
immunogenicity study, determining anti-MV neutralization. Y-axis scale represents the 
reciprocal of neutralization titer against MV. B, Results of the DENV-2 immunogenicity 
study, determining anti-DENV-2 neutralization. Y-axis scale represents the logarithmic 
neutralization index (LNI) against DENV-2. The controls were used to create the baseline 
value were sera collected from animal vaccinated with the parental strain, MVvac2, and 
reference strain, MVvac2(HBsAg)N. The horizontal dashed line shows the protective level 
of 0.7 LNI previously determined for other flaviviruses. Statistically significant differences 
are indicated by horizontal line above the experimental groups. Values from PRNT50 
neutralization assay is shown at the top of the graph.  
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of the mice vaccinated with MVvac2. In addition, the sera sample from mice vaccinated 
with two doses of MVvac2(DIII-S)N showed a higher average anti-MV neutralization 
titer of 1:1500. This measles immunogenicity study showed that receiving two doses of 
the recombinant viruses can induce similar amount of immune response against measles 
as vaccinating with only one dose of MVvac2. Therefore, the problem in reduction of 
neutralization titer against MV seen in mice vaccinated with the lower fitness 
recombinant virus can possibly be avoided by adding a second dose. 
To analyze the reactivity of the collected sera against HBsAg, we used a 
commercial ELISA kit, comparing the readings from the sera from our vaccinated mice 
to a standard curve constructed with an international reference (data not shown). For this 
experiment, the sera of the animals were pooled for each group of mice. Pooled sera from 
mice vaccinated with two doses of the reference strain, MVvac2(HBsAg)N, reached a 
titer of 648 mIU/ml. Whereas pooled sera from mice vaccinated with two doses of the 
recombinant strain, MVvac2(DIII-S,S)P, reached a titer of 787 mIU/ml. In contrast, 
pooled sera from animals vaccinated with two doses of MVvac2(DIII-S)N, did not show 
significant reactivity. As expected, the pooled sera collected from mice vaccinated with 
MVvac2, did not show HBsAg reactivity.  
To analyze the reactivity of the collected sera against DENV-2, we performed 
neutralization experiments through two different approaches. First, we analyzed the effect 
of a 1:5 serum dilution on the infection of BHK-21 cells with a 10
5
 PFU/ml DENV-2 
(Fig. 24. B). The reduction in DENV-2 infectivity caused by immune sera reactivity was 
recorded as the logarithmic neutralization index (Log10NI). Sera samples collected from 
animal vaccinated with the parental strain, MVvac2, and the reference strain, 
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MVvac2(HBsAg)N, were used as the negative controls; their values is used to set the 
baseline of the graph (Fig. 24. B). Reactivity against DENV-2 was seen in sera collected 
from mice vaccinated with MVvac2(DIII-S,S)P. We observe that those of which received 
only one dose had an average of 0.7 LNI, which shows a reduction of 5 times in DENV-2 
infection. In addition, those that received two doses of MVvac2(DIII-S,S)P had an 
average of 1.3 LNI, which shows a reduction of about 20 times in DENV-2 infection. 
Protective titer level against other flaviviruses that has been previously determined is at 
0.7 LNI. Therefore, sera collected from the mice vaccinated with two doses of 
MVvac2(DIII-S,S)P reached a higher LNI than needed for the protective level. Whereas, 
those that only received one dose reach just at the protective level of LNI. However, sera 
collected MVvac2(DIII-S)N vaccinated mice did not reach a protective level. 
The second neutralization experiment that was performed to analyze the ability of 
the mice sera to inhibit DENV-2 infection was the classic 50% plaque reduction 
neutralization assay (Fig. 24. B). Two-fold serum dilutions were incubated with 200 PFU 
of DENV-2 and the neutralization titer is determined by the dilution at which the sera 
have reduced the plaques by half, compared to a control. To determine the PRNT50 
through this experiment we used pooled mice sera for each group of mice following their 
vaccine schedule. We calculated the PRNT50 from sera pooled from mice that were given 
one dose of MVvac2(DIII-S,S)P, two doses of MVvac2(DIII-S,S)P, and two doses of 
MVvac2(DIII-S)N to be 1:10, 1:160, and 1:20 respectively. We observed that the 
PRNT50 of mice vaccinated with two doses of MVvac2(DIII-S)N is higher than those that 
received only one dose of MVvac2(DIII-S,S)P, this is the opposite of the result we 
received in the previous experiment. However, this may be due to the small amount of 
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DENV-2 epitopes that were accurately displayed causing borderline immunogenicity 
reaction against DENV-2 in this neutralization assay. Overall, the best PRNT50 titer that 
we observed through this neutralization assay resulted from the pooled mice sera from 
those receiving two doses of MVvac2(DIII-S,S)P.          
                                         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
70 
 
Chapter 4. Discussion 
 VLP platforms are very attractive vaccine candidates since they offer the 
possibility of delivering antigenic material with a structure very similar to a full virion 
and are safe because there is no risk of infection. These platforms represent the current 
vaccines for hepatitis B virus and human papillomavirus. We decided to use HBsAg as a 
platform to display domain III of the envelope protein of DENV-2 because of the 
translational strategy used for the expression and assembly of the particulate antigen. 
During hepatitis B virus infection, the viral envelope is generated by the expression of 
three envelope glycoproteins, the small, medium and large surface antigens. Their coding 
sequences have in common a 226 amino acids scaffold towards the carboxyl terminus. 
Translation starts from in-frame initiation codons, giving origin to the expression of the 
preS1 gene for the large antigen, preS2 gene for the medium antigen, and S gene for the 
small antigen. These glycoproteins of 27, 36 and 42 kDa, have the potential to self-
assemble into empty particles upon expression in infected cells with a proportion of 
4:1:1. This project explored the possibility of swapping the preS1 and preS2 regions with 
the DIII of the DENV-2 envelope glycoprotein and a bridge, creating the hybrid DIII-
HBsAg antigen. Two different recombinant viruses were then engineered using MV as 
the viral vector backbone. MV was selected to be used as the viral vector due to its safety 
and stability. We used MVvac2, which is the recombinant version of the attenuated 
strain, Moraten and Schwartz (genetically identical, despite the fact of being obtained 
separately), which is used in the current children’s vaccination schedule. We take 
advantage of the MV expression gradient to strategically place our ATUs; where the 
amount of transcription is determined by the position of the cistron relative to the 3’ end 
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of the genome. The cistron located towards the 3’ end is transcribed at a higher frequency 
due to the graduate attenuation at gene boundaries. This knowledge of the transcription of 
MV genome is factored into the engineering of our recombinant viruses. These 
recombinant viruses are termed MVvac2(DIII-S,S)P with the insertion of two ATUs and 
MVvac2(DIII-S)N with the insertion of only one ATU. 
 In MVvac2(DIII-S,S)P we co-expressed from a different locus in the MV genome 
the HBsAg protein in addition to the hybrid DIII-S, in order to promote the native 
assembly of VLPs. The proportion of these two ATUs by MV transcription gradient will 
drive a proportion of expression close to 3:1. Therefore, the generation of unmodified 
HBsAg, from the cistron located after the N cistron, can be used as a scaffold for the 
hybrid DIII-S antigen. The ATU encoding the hybrid DIII-S antigen is inserted 
downstream of the P gene. The correct construction of this full-length plasmid, 
pB(+)MVvac2(DIII-S,S)P, was confirmed through HindIII digestion and DNA 
sequencing. In figure 16, we show the observed bands from samples of the full-length 
plasmid digested with HindIII. Compared to the expected band, we conclude that the 
correct full-length plasmid was created. In addition, the DNA sequence of the full-length 
plasmid was checked for errors, and we conclude that the sequence was accurate. 
In MVvac2(DIII-S)N, we only inserted one ATU expressing the hybrid DIII-S to 
observe whether VLPs can assemble efficiently without an HBsAg scaffold.  The ATU 
encoding the hybrid DIII-S antigen is inserted downstream of the N gene and as such we 
would have expected a robust expression of the antigen. The correct construction of this 
full-length plasmid, pB(+)MVvac2(DIII-S)N, was also confirmed through HindIII 
digestion and DNA sequencing. In figure 15, we show the observed bands from one clone 
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of the full-length plasmid. We conclude that the correct full-length plasmid was created 
after the result is compared to the expected bands. The DNA sequence also confirmed the 
accuracy of the full-length plasmid. 
After confirmation of the correct sequences, we move on to rescue the 
recombinant viruses through the established reverse genetic techniques for MVs. In the 
bottom syncytia image in figure 17, we show the syncytia observed after we successfully 
rescued one of our recombinant viruses MVvac2(DIII-S,S)P. Then we continued to 
successfully rescue our second recombinant virus MVvac2(DIII-S,S)N (syncytia not 
shown). After the recombinant viruses were rescued, the viruses were passaged to create 
stock of viral prep. We were able to create a viral prep tittered at 1.8x10
5
 TCID50/ml for 
MVvac2(DIII-S,S)P and 5.6x10
7 
TCID50/ml for MVvac2(DIII-S)N. These titers are high 
enough for us to move forward with additional experiments, which also include our 
animal experiments.  
The next step of the experiments was to analyze the replication fitness of the 
recombinant MVs compared to the parental strain, MVvac2, and the reference strain, 
MVvac2(HBsAg)N. The multiple-step growth kinetics that was performed showed a 
decrease in the replication fitness of MVvac2(DIII-S,S). The decrease of viral production 
compared to MVvac2 and MVvac2(HBsAg)N was concluded to be result of the two 
ATUs inserted into the MV genome. Although the two ATUs were inserted in non-
sequential locus of the genome, the increased size of the genome may also account for the 
drop of MV infectivity progression. Furthermore, it makes sense to conclude that more 
insertions lead to a dilution of the genes downstream the insertions. Those genes are 
important for measles replication (like the polymerase, L gene) In addition, this negative 
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effect on the replication of recombinant MVs have been observed in other research 
utilizing MV vectors with multiple insertion of ATUs. On the other hand, this negative 
effect of the recombinant virus’ replication fitness was not observed in MVvac2(DIII-
S)N which makes us conclude that the gene DIII-SA is not by itself  incompatible with 
measles replication.. Our second recombinant virus followed a similar replication fitness 
as the parental strain, MVvac2. In addition, it also follows the replication fitness of 
MVvac2(HBsAg)N, which also have one ATU encoding HBsAg. This supports the idea 
that only one ATU insertion into the MV genome was not able to affect its replication 
fitness, whereas the insertion of two ATUs was able to affect it negatively. The results 
from the multi-step growth kinetics is statistically valid, since it shows the corroborated 
average data from experiments repeated independent of each other.  
 Next, we performed an ELISA against HBsAg to confirm the production of 
HBsAg. This experiment was done as an initial assessment of the possible production of 
HBsAg from the recombinant MVs. Hence it was performed only using the supernatants 
collected from MVvac2(DIII-S,S)P infected cells, as well as the supernatants from 
MVvac2(HBsAg)N infected cells as the control. Samples of the supernatants were 
collected at different time-points post-infection. The result from the Anti-HBsAg ELISA 
showed the presence of HBsAg in the supernatant from MVvac2(DIII-S,S)P infected 
cells. Data above the dashed line (Fig. 19) showed the significant value, which represents 
the HBsAg present. However, we were not able to state any quantitative data from this 
experiment, because the assay shows only the possibility to discern positive from 
negative; due to the sensitivity of this specific ELISA kit. We plan to standardize this 
experiment in order to supplement the replication kinetics we collected. Therefore this 
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experiment was a supplement to the replication kinetics we collect. However, we 
characterized the production of HBsAg, as well as the hybrid DIII-HBsAg antigen, in a 
more precise approach, by protein immunoblots. 
The results from the characterization of the expression of hybrid DIII-HBsAg 
antigen (Fig. 20) solidified that DIII-S hybrid glycoprotein was indeed expressed in 
infected cell extracts.  We were able to corroborate that each sample contained the same 
amount of protein extract, as shown by the bottom western blot (Fig. 20) that is 
developed by the antibody against the N protein of MV. In the experimental sample, there 
is a clear upward shift of the double band in the sample collected from the protein 
extracts from cells infected with MVvac2(DIII-S,S)P representing the higher size of the 
protein with the addition of DIII from DENV-2. This can be easily compared to the 
control sample of protein extracts from cells infected with MVvac2(HBsAg)N, which 
only show one set of double bands at a lower size. However, the upwardly shifted double 
bands corresponding to the glycosylated (37 kDa) and non-glycosylated (34 kDa) 
isoforms of the hybrid antigen is shown to be at a lower quantity, by the intensity of the 
bands (Fig. 20). We concluded that this was due to the location of the ATU that is 
inserted encoding the hybrid DIII-S antigen, which is downstream of the P gene. 
Following the MV genome transcription gradient, this means that it was transcribed at a 
lower quantity due to its location. In addition, the amount of the native HBsAg 
glycosylated (27 kDa) and non-glycosylate (24 kDa) isoforms present in the sample from 
the MVvac2(DIII-S,S)P infected cells is similar to the same isoform in the sample 
collected from cells infected with the reference strain. Overall, from this initial 
characterization experiment, we were able to confirm from our western blots, the 
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successful expression of the hybrid DIII-HBsAg antigen from one of our recombinant 
MV, MVvac2(DIII-S,S)P. The next step we took was then to characterize both of our 
recombinant MVs for the production of the hybrid antigen.  
The characterization for the expression of the hybrid DIII-HBsAg antigen was 
repeated with both recombinant MVs. The experiment was performed in the same way as 
the previous one. However, the western blots were containing the same samples, were 
developed with anti-HBsAg monoclonal antibody (Fig. 21. A) and anti-DIIII DENV-2 
monoclonal antibody (Fig. 21. B). As expected, the upward shifted band that was seen in 
the sample from cells infected with MVvac2(DIII-S,S)P is present again in this western 
blot. We also see again the lower intensity of the bands at 37 kDa and 34 kDa. The bands 
corresponding to the native HBsAg can also be seen in the samples form cells infected 
with MVvac2(DIII-S,S)P and MVvac2(HBsAg)N. However, bands showing any 
reactivity were not seen in the protein extract from cells infected with MVvac2(DIII-S)N, 
concluding that the insertion of DIII into HBsAg, in the absence of HBsAg alone is not 
compatible with the recognition by our antibody. The reactivity of the anti-HBsAg 
antibodies highly depends on the conservation of the semi-native structure of the 
protein’s epitopes, which is the reason why this western blot was run under non-reducing 
conditions. This monoclonal detects a region on HBsAg that is termed he “a” epitope that 
is essential for proper folding of HBsAg. We propose that the sole expression of DIII-S 
hybrid antigens leads to an unfolded product that is certainly tagged for degradation. 
Therefore, we suggest that the additional native HBsAg is needed to scaffold the DIII-S 
antigen, which will result in the correct protein structure that will be recognized by the 
antibody. In order to confirm that the expressed hybrid DIII-S antigen also presented the 
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DENV-2 epitopes shown in DIII, a western blot was developed with a monoclonal 
antibody specific to DIII of the DENV-2 envelope protein (Fig. 21. B). Here we observed 
two bands at 37 kDa and 34 kDa in both samples of protein extracts from cells infected 
with MVvac2(DIII-S,S)P and MVvac2(DIII-S)N. These bands correspond to the same 
bands in the western blot developed with anti-HBsAg antibodies, which represents the 
glycosylated and non-glycosylated isoforms of the hybrid antigen. The intensity of the 
bands was observed to be weak in the sample from cells infected with MVvac2(DIII-S)N, 
which supports the conclusion that the expressed hybrid antigen degraded and misfolded. 
In addition, a western blot containing the same samples was also developed with 
antibodies against the N protein of MV to corroborate that the same amount of each 
sample were used (data not shown). Therefore, we were able to confirm the expression of 
the correct DENV-2 epitope present in DIII from one of our recombinant MV, 
MVvac2(DIII-S,S)P. However, we suggest that MVvac2(DIII-S)N may be expressing an 
incorrectly folded hybrid DIII-HBsAg.    
The next experiment that we performed was done to confirm the successful 
construction of hybrid viral-like particles. This was done by using a discontinuous 
sucrose gradient to fractionate by density samples collected from supernatants of cells 
infected with MVvac2(DIII-S,S)P of MVvac2(HBsAg)N. Due to the inability of the anti-
HBsAg antibody to recognize the hybrid antigen produced by MVvac2(DIII-S)N (Fig. 
21. B), this experiment was focused on the first recombinant virus MVvac2(DIII-S,S)P. 
MVvac2(HBsAg)N was used as a positive control, and cells were infected with the 
reference strain in parallel, because their ability to secrete VLPs following a specific 
sucrose density has been previously documented by other researchers. In the western blot 
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of the nine fractions collected from the supernatants of cells infected with MVvac2(DIII-
S,S)P, developed with anti-HBsAg, we observed the upward shifted double bands 
corresponding to the hybrid DIII-HBsAg bands in fractions 4 to 5, shown with arrows 
(Fig. 22). We also observe the double bands corresponding to the native HBsAg in the 
western blots from both the recombinant strain and reference strain fractions; these are 
also sequestered in fraction 4 to 5 at a sucrose density of 1.10-1.12 g/ml. Therefore, we 
can conclude that the biophysical characteristics of the HBsAg subviral particle were not 
changed or affected by the incorporation of DIII, because the hybrid VLPs and the native 
HBsAg VLPs were sequestered in the same fractions and at the same density. In addition, 
the last western blot that was done (Fig. 22. B) was developed by antibodies against the N 
protein of MV, using fractions collected from the supernatants of cells infected with 
MVvac2(DIII-S,S)P. This western blot shows that the MV viral particles are sequestered 
at more dense fractions, fraction 6 to 9. This supports the notion that HBsAg- and hybrid-
VLPs are secreted independently of the MV viral particles and that the production of the 
VLPs did not negatively affect the production of MV viral particles. Overall, we 
confirmed the successful incorporation of DIII in the hybrid VLPs, without affecting the 
antigenic characteristics of the VLPs. 
After we have established that the hybrid antigen DIII-HBsAg can be expressed 
by our recombinant MVs and that viable hybrid VLPs can be produced, we moved 
forward with the most important experiments in our animal models. Two animal 
experiments were performed, using two different types of transgenic mice; sera collected 
from these animal experiments were then used for an immunogenicity study. The first 
animal experiment was done in HDD-SLAM-IFNar
KO
 transgenic mice. These mice were 
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vaccinated with the controls: parental strain, MVvac2, reference strain, 
MVvac2(HBsAg)N, and the positive control, DENV-2; as well as the experimental 
recombinant virus, MVvac2(DIII-S,S)P. In the immunogenicity study against measles, 
we observed a four-fold reduction of neutralization in sera from mice vaccinated with 
MVvac2(DIII-S,S)P compared to the parental strain, MVvac2 (Fig. 23). However, we 
also observed a two-fold reduction of neutralization in sera from mice vaccinated with 
MVvac2(HBsAg)N. This data would support the theory of the decrease in viral fitness 
based on the amount of ATUs inserted into the MV genome. Insertion of one ATU 
resulted in a two-fold reduction in neutralization and the insertion of two ATUs resulted 
in a four-fold reduction in neutralization. This will be a valuable knowledge for future 
construction of recombinant MVs.  
In the immunogenicity study against hepatitis B and DENV-2, we observed 
reactivity for both in our experimental sample (Fig. 23). The result of the anti-HBsAg 
ELISA showed that the sera from mice vaccinated with MVvac2(DIII-S,S)P were able to 
reach the protective titer of 10 mIU/ml. However, the eight-fold reduction in its anti-
HBsAg titer may be caused by the use of HBsAg in creating the hybrid VLP, which may 
cause a specific amount of the antigenic epitope of HBsAg to be hidden from the surface 
of the VLPs. The result of the homemade ELISA to analyze the reactivity of the sera to 
DENV-2, shows two sera samples from mice vaccinated with MVvac2(DIII-S,S)P that 
clearly reacted to DENV-2. The sera that came from these two mice were also the ones 
that had the highest measles neutralization titer at 1:426 and 1:266, as well as the highest 
anti-HBsAg titer at 54 mIU/ml and 13 mIU/ml, from the group of 5 mice vaccinated with 
MVvac2(DIII-S,S)P, which supports the notion that a robust anti-HBsAg immunity is 
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accompanied by Dengue 2 recognition. Although the mice vaccinated with DENV-2 was 
supposed to be the positive control. We realized at a later time, that these mice were 
given a dose of 10
2
 PFU instead of 10
5
 PFU, which may have resulted in the lack of 
immune response that was induced in these animals. Overall, the ELISA against DENV-2 
only shows reactivity of the sera, not quantifying its neutralization capability. Therefore, 
a neutralization assay for DENV-2 was performed from the animal sera collected from 
the second animal experiment, to present a more accurate data.  
In the second animal experiment, huCD46Ge-IFNar
KO
 transgenic mice were 
vaccinated with the controls: the parental strain, MVvac2, and the reference strain, 
MVvac2(HBsAg)N; as well as the experimental recombinant MVs: MVvac2(DIII-S,S)P 
and MVvac2(DIII-S)N. Different groups of animal received different doses as shown in 
figure 24. In the immunogenicity study against measles, we observed a similar reduction 
in anti-MV neutralization titer in the sera collected from animals vaccinated with one 
dose of MVvac2(DIII-S,S)P, as the previous animal experiment. Again, we believe that 
this is caused by the reduced viral replication fitness due to the insertion of two ATUs, as 
documented in vitro from our multi-step growth kinetics (Fig. 18). However, we 
observed that this negative effect from the weaker viral fitness can be solved by the 
administration of a booster dose. The anti-MV neutralization titer of the sera collected 
from mice which received two doses of MVvac2(DIII-S,S)P is comparable to that of the 
parental strain, MVvac2 (Fig. 23. A). In addition, the other groups of animal which also 
received two doses, MVvac2(HBsAg)N and MVvac2(DIII-S)N, also showed an anti-MV 
neutralization titer comparable to the animals that was vaccinated with MVvac2. 
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The immunogenicity study against hepatitis B was done through the use of a 
commercial ELISA. There were no significant reactivity seen in the pooled sera collected 
from animals that received one dose of MVvac2(DIII-S,S)P, two doses of MVvac2(DIII-
S)N, or as expected, one dose of MVvac2 (data not shown). However, we did observed 
an anti-HBsAg titer of 787 mIU/ml from mice vaccinated with two doses of 
MVvac2(DIII-S,S)P and 648 mIU/ml from mice vaccinated with two doses of 
MVvac2(HBsAg)N. As previously witnessed, the administration of two doses of the 
recombinant virus highly increases the immune response induced. In the immunogenicity 
study against DENV-2, two different types of neutralization assays were performed. The 
result of the first approach, recorded in Log10NI, shows a strong neutralization capability 
of sera collected from mice vaccinated with two doses of MVvac2(DIII-S,S)P; although 
the mice that received only one dose was able to reach the protective titer for reference 
flaviviruses (such as YFV and JEV) of 0.7 LNI. This result gave additional support to the 
theory that the administration of a booster shot may be needed to induce a completely 
protective immune response. On the other hand, the sera from mice vaccinated with two 
doses of MVvac2(DIII-S)N did not reach a protective titer. This may be caused by the 
improper folding of the hybrid DIII-HBsAg, resulting in the improper construction of the 
hybrid VLPs produced by this recombinant virus, as we have previously suggested. The 
second neutralization assay done against DENV-2, was the classic PRNT50.  Once more 
the result of the neutralization capability of the sera collected from the mice that received 
two doses of MVvac2(DIII-S,S)P was shown to be the strongest. However, the pooled 
sera from mice that received only one dose of MVvac2(DIII-S,S)P had a lower PRNT50 
titer than those that received two doses of MVvac2(DIII-S)N. It is possible that this 
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happened due to the presence of a few properly expressed DENV-2 epitopes that was 
previously seen in a western blot developed with anti-DIII DENV-2 (Fig. 21. B); this 
may have caused a minimal immunogenicity reaction against DENV-2 in this 
neutralization assay. Throughout the immunogenicity study, the animals that received 
two doses of MVvac2(DIII-S,S)P consistently showed higher immunogenicity against all 
three viruses.  
The stability of the recombinant viruses could be observed through the presence 
of the bands in an immunoblot from samples of different passages. MVvac2(DIII-S,S)P 
have been amplified to reach passage 5, and the double bands corresponding to the DIII-S 
antigen from these samples can still be observed in an immunoblot. However, 
MVvac2(DIII-S)N have only been amplified to passage 3, and this was the passage used 
in all of the experiments concerning this recombinant MV. Further experiments are still 
needed to fully confirm the stability of the recombinant MVs, which include sequencing 
each passage of the virus as well as a serial passaging experiment. The result from these 
experiments will then be able to determine whether the viral genome remains unaffected 
through multiple passages.  
Overall, we were able to confirm the successful construction of the recombinant 
MVs and analyzed their capability of eliciting immune response in the immunogenicity 
studies. In MVvac2(DIII-S,S)P, we demonstrated the correct assembly of our hybrid 
antigen and the release of the hybrid subviral particles in the supernatants of infected 
cells. In addition, this recombinant MV was able to induce a protective neutralizing 
immune response against all three viruses: MV, HBV, and DENV-2. Although we were 
not able to detect the successful secretion of the hybrid antigen from MVvac2(DIII-S)N 
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by anti-HBsAg, we confirmed that its replication fitness mirrored that of the parental 
strain, we were able to see it elicit immune response against measles, as well as express 
marginally some antigens that are recognized by the anti-DIII DENV-2. The result of our 
animal experiments also shows the importance of the vaccination dosage, as the animals 
that received two doses of MVvac2(DIII-S,S)P elicited the strongest immune response. 
Although we were not able to detect viable hybrid subviral particles secreted from 
MVvac2(DIII-S)N, we suggests that this is due to the lack of native HBsAg VLP that was 
available to scaffold the hybrid DIII-S antigen. In order to clarify this theory, we will 
perform a co-infection experiment using MVvac2(DIII-S)N and MVvac2(HBsAg)N 
We decided to use HBsAg to create our hybrid VLP, because HBsAg 
independently creates its own VLP and it is also used in an approved human vaccine 
against hepatitis B. As shown in our results, the production of additional native HBsAg is 
necessary in the accurate assembly of the hybrid VLPs. In addition, our use of MV as the 
viral vector serves the purpose of a live adjuvant in the form of a live attenuated virus, 
which has been proven to be safe and stable.  
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Chapter 5. Conclusion 
 This is a proof-of concept for an ideal pediatric vaccine that would protect an 
individual against DENV, Hepatitis B virus, and MV. Using MV as a viral vector will 
make the production and distribution of this recombinant vaccine to be efficient and cost 
effective; mainly due to the system that is already in place for the production and 
distribution of MV based vaccines. In addition, this vaccine would be a safe option, since 
the Moraten/Schwartz vaccine strain used has been proven to have long-term safety. Our 
data confirms immunogenicity in MV susceptible animal models against all three: 
DENV, Hepatitis B virus and MV. The heightened immune response seen in animal who 
received two doses suggests that to achieve complete protection in humans, booster 
vaccination may be necessary. 
Chapter 6. Future Perspective 
In future experiments, we would like to look for possibilities of increasing the 
viral fitness of our recombinant MVs. As well as the possibility of avoiding the decrease 
in viral fitness by inserting only one ATU into the MV genome, but inoculating in vivo, 
with two recombinant MVs expressing the additional HBsAg needed. To circumvent the 
replication problem that having two ATUs originate, we propose to invert the order of 
insertion: DIII-S after N and HBsAg after P, which will increase the expression of the 
hybrid antigen and conserve a scaffold of HBsAg to construct the particle. Alternatively, 
we can infect cells with two separate vectors and collect the supernatant form co-infected 
cells. Arguably, if both antigens are expressed in the same syncytia, then hybrid VLPs 
will be secreted, it is tempting to think that MV virion with two genome can be 
assembled and propose and original solution to multiple insertion. 
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